KR20150044817A - Compositions comprising paulownia tomentosa wood extracts and uses thereof - Google Patents

Abstract

Provided are compositions comprising Paulownin or Paulownia tomentosa wood extracts and methods of use thereof.

Description

TECHNICAL FIELD The present invention relates to a composition comprising a wood extract of Paulownia tautentosa and a use thereof. BACKGROUND OF THE INVENTION 1. Field of the Invention < RTI ID = 0.0 >

Cross reference to related application

This application is a continuation-in-part of U.S. Patent Application No. 13 / 211,626 filed on August 17, 2011, which is a continuation-in-part of U.S. Patent Application No. 12 / 859,323 filed on August 19, 2010.

The present invention relates to a composition comprising Paulownin for use on the skin. The present invention also relates to a composition comprising plant extracts from the genus Paulownia for use on the skin. More particularly, the present invention relates to a composition comprising an extract of Paulownia tomentosa wood for a variety of uses on the skin.

Paulunia is a genus of plants originating in Asia and gradually spreading to Europe and the United States. Species from Paulini subspecies are generally regarded as ornamental trees with a wide range of craft applications and ecological applications in the wood. For example, such wood timber is popular for the production of stringed musical plates in Japan, China and Korea. It is also popular with timber merchants for use in furniture manufacturing. The paulownia tree has ecological uses and is considered a phyto-remediator, that is, the tree can help clean up and clear the land by treating industrial pollutants through its piping system.

In Japan, Paulo Unia is called "kiri", which is a kind of "Paulownia Tontentosa", also called "the True Tung Tree" (Princess Tree). Other commonly used names are "empress tree", "Foxglove Tree", "Royal Paulownia", "Pao tong" (in China) and " It is "Odong-Namoo" (in Korea). The scientific name is "Pauline Astrology" and many synonyms are reported in various literatures: "Paulownia imperialis", "Paulownia recurva", " And "Bignonia tomentosa ". Pauluniatomentosa belongs to the "Paulynia" and is often referred to as "Scrophulariaceae". The US Department of Agriculture's (Plants.USDA.gov) database identifies paulownia trees with a unique designation "PATO2", with similar names for Paulownia Tontentosa and Paulunia Imperiallis.

Flower oil from Pauluniatomentosa is well studied and has been found to be richer in aroma compared to other species. The antioxidant activity from flower extracts and antiviral properties from stem bark are determined by the number of viability, for example, anticancer composition from flower extract, antiparasitic activity from unspecified extract, antimicrobial activity from fruit and flower extract, It is associated with the extracts of various parts of the niacin. Leaf extracts of Paulownia are described for hair growth and hair growth properties.

Also known as isoflavonein or neopowloinin, faurolone is a lignan isolated from the underside of various plants. The chemical structure can be given as follows:

The present invention relates to the discovery of the present inventors that the extract of Pauloniia Tontentosa wood is beneficial for use in compositions on the skin. For example, the inventors have found that such compositions tend to exhibit significant and unexpected characteristics to the skin, including skin lightening, improved signs of aging, and reduced inflammation. The present invention also relates to the discovery of the present inventors that the paurolone compounds exhibit significant and unexpected skin lightening, anti-aging effects and other properties.

In one aspect, the invention relates to a composition comprising a paurolone and a carrier.

In another aspect, the present invention relates to a method of improving the signs of skin aging, comprising applying to the skin a composition comprising the paurounin and the carrier in need of such improvement.

In another aspect, the present invention relates to a composition comprising an extract and a carrier of Pauluniatomentosa wood.

In another aspect, the present invention relates to a skin lightening method comprising applying an extract of Pauluniatomontosa wood to skin requiring a skin lightening treatment.

In another aspect, the present invention relates to a method of improving the signs of skin aging comprising the step of applying an extract of Paulownia tautentosa wood to the skin in need of such improvement.

In another aspect, the present invention relates to a method of reducing skin inflammation, comprising applying an extract of Paulownia tautentosa wood to skin requiring reduction of skin inflammation.

As indicated above, the present inventors have unexpectedly found that the extracts of fullerenine and / or pauloniaitomentosa wood are effective in the compositions, preferably in skin care compositions, and in improving aging symptoms, skin lightening and inflammation reduction But can be used in methods of use not limited thereto.

As used herein, the term "skin lightening" is generally used to mean lightening, brightening, whitening and / or evening skin tone, skin color, and / And / or reduction of sallowness and / or pigmented spot, melanin spot, aging spots, sun spot, senile lentigo, freckles, simple blacks, pigmented day keratoses, And / or fading pigmented superficial marks and / or lesions including, but not limited to, dermatitis, spots, acne marks, hyperpigmentation after inflammation, surplus, nevus, combinations of two or more thereof It says. In certain embodiments, "skin lightening" may also be used to enhance skin lightness, flushing, translucency and / or luminescence, and / or more radiant, flushing, translucent or glowing skin tone appearance, It is said to obtain a yellowish skin tone. In certain preferred embodiments, "skin lightening" refers to brightening and evenening skin tone, increasing skin radiance and / or brightening aging spots.

As used herein, the phrase "skin requiring skin lightening treatment" refers generally to skin that exhibits one or more properties selected from the group consisting of: those described herein, As measured according to COLIPA GUIDELINE: GUIDELINE FOR THE COLORIMETRIC DETERMINATION OF SKIN COLOR TYPE AND PREDICTION OF THE MINIMAL ERYTHEMAL DOSE (MED) WITHOUT UV EXPOSURE, published in 2007, Dark / yellowish skin including skin darkened by UV, skin with uneven skin tone, or colored spots, melanin spots, aging spots, daylight spots, senility Blackness, freckles, simple blackness, colorectal keratosis, bruising keratosis, spots, acne marks, hyperpigmentation after inflammation, surplus, Bones, skin with one or more pigmented deposits and / or lesions, including, but not limited to, combinations of two or more of these. In the COLIPA guidelines, skin color is defined as a function of the ITA value as follows: very light skin: >55; Light skin: 41-55, Medium: 28-41, and tan skin: <28. In certain preferred embodiments, "skin requiring skin lightening" is a skin having an ITA value of less than 41, such as less than about 40, less than about 35, less than about 30, or more preferably less than about 28 . In certain other preferred embodiments, the present invention relates to compositions and methods of use for skin requiring skin lightening treatment selected from yellowish and / or dark skin. In certain other preferred embodiments, the present invention relates to compositions and methods of use for skin requiring skin lightening treatment selected from the group consisting of aging spots, freckles, marks left after acne, and combinations of two or more thereof.

As used herein, "a skin that requires improvement in aging symptoms" refers to a skin that does not exhibit any symptoms, including, but not limited to, sagging skin, sagging skin, loosened skin, rough skin, wrinkled skin, thinned skin and uneven skin it means. Improvement of signs of aging can be achieved by improving the firmness of the skin, improving the texture of the skin, improving the appearance of wrinkles in the skin, improving the skin tone, or treating external aggression it means.

As used herein, "improvement of skin firmness" means improving the firmness or elasticity of the skin, preventing the firmness or loss of elasticity of the skin, or preventing or treating sagging, loosened and stretched skin. The firmness or elasticity of the skin can be measured by use of a skin elasticity meter. Handbook of Non-Invasive Methods and the Skin, eds. J. Serup, G. Jemec & G. Grove, Chapter 66.1 (2006). Loss of skin elasticity or firmness may be a result of many factors including, but not limited to, the result of aging, environmental damage, or application of the cosmetic to the skin.

As used herein, "improving skin texture" means softening the skin surface to remove bumps or crevices on the surface of the skin.

As used herein, "improvement in appearance of wrinkles in the skin" means preventing, delaying, inhibiting, or reversing wrinkles and fine lines in the skin.

As used herein, "treatment of an external attack in the skin" means reducing or preventing damage due to external attack in the skin. Examples of external attack include use of a cleanser (e.g., a topical cleanser containing a surfactant), cosmetic damage to the skin due to shaving, as well as environmental damage such as UV light (e.g., sun damage Or damage from non-natural sources such as UV lamps and solar simulators), ozone, exhaust gases, pollution, chlorine and chlorine containing compounds, and damage from tobacco smoke. The effects of external attack on the skin include, but are not limited to, modifications to lipids, carbohydrates, peptides, proteins, nucleic acids and vitamins and oxidative and / or nitropic damage thereto. The effect of external attack on the skin also includes, but is not limited to, loss of cell viability, loss or alteration of cell function, and changes in gene and / or protein expression.

As used herein, "improvement of skin tone" refers to lightening of the skin's appearance (e.g., lightening of pigmented marks or lesions, reduction of yellowishness of skin and / or uniformity of skin color).

As used herein, "skin requiring reduction of skin irritation" means skin that shows redness or redness, edema, or is reactive or sensitive to external factors. The external elements include, but are not limited to, sunlight (UV, visible light, IR), microorganisms, air pollutants such as ozone, exhaust pollutants, chlorine and chlorine generating compounds, tobacco smoke, . Inflammatory disorders and related conditions that can be treated or prevented by the use of the compositions of the present invention include, but are not limited to, arthritis, bronchitis, contact dermatitis, atopic dermatitis, psoriasis, seborrheic dermatitis, eczema, allergic By extrinsic factors including but not limited to dermatitis, polymorphic light emission, inflammatory skin disease, folliculitis, alopecia, poison ivy, acne inflammation, chemicals, trauma, pollutants (eg tobacco smoke) Secondary conditions arising from inflammation, including, but not limited to, induced irritation, dryness, hyperkeratosis, pruritus, hyperpigmentation after inflammation, scarring and the like. Preferably, the inflammatory disorder and related conditions that can be treated or prevented using the methods of the present invention are selected from the group consisting of arthritis, inflammatory skin diseases, contact dermatitis, allergic dermatitis, atopic dermatitis, polymorphic light emission, Irritation including erythema, acne inflammation, psoriasis, seborrheic dermatitis, eczema, lacquer, insect pox, folliculitis, alopecia, and secondary condition.

As used herein, unless otherwise specified, all percentages of the components in the composition are weight percent of the active / solid component based on the total weight of the composition.

As used herein, a composition in which a component is "essentially non-existent " means a composition having the component in an amount of about 2% by weight or less based on the total weight of the composition. Preferably, the composition in which the component is essentially free is present in an amount of up to about 1% by weight, more preferably up to about 0.5% by weight, more preferably up to about 0.1% by weight, About 0.05 or less, and more preferably about 0.01 weight% or less. In certain more preferred embodiments, a composition in which there is essentially no component is free of that component, i. E. It has no component in the composition.

As used herein, the term " cosmetically / dermatologically acceptable "means that the ingredients described by the term are intended to encompass tissues (e. G., Skin or skin) without undue toxicity, incompatibility, instability, irritation, Hair) of the present invention.

The extract containing the paulonin may be one or more fractions of the material derived from the paulownia tautentosa wood through any of the extraction methods described herein, or may be made of such fractions. In certain embodiments, the extract comprises one fraction, or a combination of two or more fractions, from a wood of Pauluniatomentosa.

Any suitable extract of the Pauluniatomontosa wood can be used according to the invention. In general, the wood of the Pauluniatomentosa tree comprises wood from a stem, a branch, or a combination of both. Suitable extracts of wood from Pauluniatomentosa can be derived from wood chips, wood dust and / or small cuttings.

A suitable extract of wood is directly extracted from the wood by processes such as grinding, cold pressing, pressing, squeezing, mashing, centrifugation, and / or cold percolation and shaking / Supercritical / supercritical CO ₂ compressed gas extraction with or without polar modifier, pressurized solvent extraction, accelerated solvent extraction, pressurized or normal hot water extraction, surfactant assisted pressurized hot water extraction , Oil extraction, membrane extraction, Soxhlet extraction, Gold finger distillation / extraction, and / or other techniques such as, for example, US Pat. Nos. 7442391 and 7473435 (Integrated Botanical Technologies, LLC) , And the processes described in U. S. Patent No. 7537791, etc., or by other methods such as solvent extraction, etc. . Any solvent in various solvents, including polar solvents, non-polar solvents, or combinations of two or more thereof, may be used in a process comprising solvent extraction. Suitable polar solvents include polar organic solvents such as water and the like, alcohols and corresponding organic acids such as C ₁ -C ₈ alcohols including methanol, ethanol, propanol, butanol and the like and organic acids including acetic, formic, Organic solvents, polyols and glycols including C ₁ -C ₈ polyols / glycols and the like, and combinations of two or more thereof. Suitable non-polar solvents are ketones, including alkyl ether, petroleum ether, C ₁ -C ₈ ketones, including cyclo alkanes, C ₁ -C ₈ alkyl ethers, including alkanes, C ₁ -C ₈ alkanes, including C ₁ -C ₈ alkane, And nonpolar organic solvents such as methylene chloride, ethyl acetate, xylene, toluene, chloroform, vegetable oil, mineral oil and the like. In yet another embodiment, the extraction is carried out with a polar modifier such as a C ₁ -C ₈ alcohol, water, a C ₁ -C ₈ polyol / glycol or a C ₁ -C ₈ organic acid, or a supercritical fluid extraction without a polar modifier, Solvent. &Lt; / RTI &gt; In certain preferred embodiments, the extract of the present invention is obtained by micronizing the wood and having a dielectric constant value of 1 to 100 at 20 DEG C, preferably a dielectric constant value of 4 to 60 at 20 DEG C, more preferably 4 With a dielectric constant value of from 4 to 40 at 20 &lt; 0 &gt; C, and even more preferably with a polar solvent having a dielectric constant value of from 4 to 40 at 20 &lt; 0 &gt; C. Examples of preferred polar solvents are C ₁ -C ₈ alcohols, C ₁ -C ₈ polyols / glycols having a dielectric constant value of 1 to 100, preferably 4 to 60, and more preferably 5 to 40 at 20 ° C, C ₁ -C ₈ organic acids, water, and combinations of two or more of these, as described in "Dielectric Constants of Some Organic Solvent-Water Mixtures at Various Temperatures," Akerlof, Gosta; JACS, Vol. 54, No. 11 (Nov. 1932), pp. But are not limited to, combinations of such solvents and solvents having desired dielectric constant values such as those disclosed in U.S. Pat. No. 4,125-4139. In certain preferred embodiments, the polar extract is extracted using one or more C ₁ -C ₈ alcohols, C ₁ -C ₈ polyols, C ₁ -C ₈ glycols, and combinations of two or more thereof. In certain more preferred embodiments, the extract is extracted using one or more C ₁ -C ₄ alcohols, C ₁ -C ₄ polyols, and / or C ₁ -C ₄ glycols. In certain more preferred embodiments, the extract is prepared using a solvent comprising methanol, ethanol, or a combination thereof in the presence or absence of water. In a more preferred embodiment, the extract is prepared using anhydrous alcohol or reagent grade denatured alcohol, and is dried with shaking at room temperature for 3 days. In certain preferred embodiments, the extract may be further smelted by treatment with charcoal (also referred to as activated charcoal).

In certain embodiments, the extract of Paulownia tontentosa may be prepared with essentially no specific material. In one embodiment, the extract is essentially free of uricolic acid, beta-sitosterol, or both.

In certain embodiments, the composition may further comprise an extract from one or more of the other parts of the Pauluniatomentosa, for example, bark, leaf, root, fruit, seed or flower. In another embodiment, the composition is essentially free of extracts from other non-wood parts of PaulowniaTomentosa.

The present invention further relates to a skin care composition comprising a faurolinine, a skin treatment method, for example a skin lightening method, a method for treating at least one skin aging symptom, a method for treating inflammation, By applying a composition comprising a compound of formula &lt; RTI ID = 0.0 &gt; to &lt; / RTI &gt;

파울로우닌

Paulonin

The poulonin for use in the present invention can be derived from any of a variety of natural sources, such as extracts from plants, or can be synthesized using known synthetic methods (see, for example, Stereoselective Synthesis of 3- Alkyl-2-aryltetrahydrofuran-4-ol: Total Synthesis of (+) - Paulownin. Angle, Steven R .; Choi, Inchang; Tham, Fook S. Department of Chemistry. (2008), 73 (16), 6268-6278), and total synthesis of (+) - paulownin. Okazaki, Momotoshi; Ishibashi, Fumito; Shuto, Yoshihiro; Taniguchi, Eiji. , Matsuyama, Japan, Bioscience, Biotechnology, and Biochemistry (1997), 61 (4), 743-745). In certain preferred embodiments, the faurosine is extracted from the plant. Examples of suitable plants include plants of the genus Paulownia , such as, for example, Paulownia tautentosa, Paulownia fortunei , Paulownia elongata , Paulownia kawakamii , , Other plants such as Amanoa oblongifolia , Dolichandrone crispa , Firmiana platanifolia , Gmelina arborea, Melina Asia Gmelina asiatica , Gmelina vitiensis , Isodon parvifolius, Kigelia pinnata , Markhamia platycalyx , Marquamia mica , Such as Markhamia stipulate , Millingtonia hortensis , Olea species, Phyllarthron comore, nse , Tabebuia incana , Vitex trifolia , Prasium majus , combinations of two or more of these, and the like. In certain preferred embodiments, the faurolone is extracted from the wood of Pauluniatomentosa.

In certain embodiments, the poulouninin can be obtained through extraction of cell cultures of various plants, including cell cultures of plants of the genus Paulownia, e.g., pouloniatistomentosa. The cell culture to be extracted for obtaining the extract / faurolinine for use in the present invention may be any form including a suspension cell culture and the like.

Any suitable amount of fullerenine or PaulowniaTomentosa wood extract can be used in the compositions of the present invention. Preferably, the composition comprises a safe and effective amount of a paurounin or a Pauluniatomentosa wood extract. As used herein, "safe and effective amount" means an amount or amount of the extract that is sufficient to cause the desired effect, but low enough to avoid serious side effects, including cytotoxicity and the like. In embodiments involving skin lightening applications of the composition, the "amount effective for skin lightening" is an extract effective to achieve a? L value greater than 0 in the skin epidermal equivalent model as a skin lightening test (? L) . In certain preferred embodiments, the skin whitening effective amount is an amount effective to achieve a? L value of about 1 or greater.

In an embodiment of the present invention relating to the use of the composition in improving the signs of aging in the skin, "an amount effective for improving signs of aging" is determined by the inhibition of the UV-induced MMP induction procedure of Example 11 below Quot; means an amount that provides MMP-1 or MMP-9 production inhibition (%) greater than zero. In certain preferred embodiments, the amount effective for aging symptom improvement provides an MMP-1 or MMP-9 production inhibition (%) of at least about 10% when measured according to the inhibition of the UV-induced MMP induction procedure of Example 11 below It is a quantity. In certain preferred embodiments, the amount effective to ameliorate the aging symptom is the amount of Reactive Oxygen Species (ROS) formation in the reconstituted epidermis and in human epithelial cells, respectively, given in Examples 8 and 9 below (%) Of reactive oxygen species (ROS) that is greater than or equal to about 10%, and preferably greater than or equal to 20% when measured according to the inhibition of ROS.

In an embodiment of the present invention relating to the use of the composition in reducing inflammation, the "amount effective for reducing inflammation" refers to the amount of UV-induced proinflammatory mediator on the reconstituted epidermis of IL- Means an amount that provides a percent inhibition of skin inflammation (IL-8) greater than 0 when measured according to the procedure for anti-inflammatory effects on release. In certain preferred embodiments, the amount effective to ameliorate signs of aging is according to the procedure for anti-inflammatory effects on the release of UV-induced proinflammatory mediators on reconstituted epidermis in IL-8 of Example 7 below (%) Of greater skin inflammation (IL-8) that is greater than about 10% when measured.

In certain preferred embodiments, the composition comprises greater than 0% to about 20% of a paurounin or a Pauluniatomentosa wood extract. In certain other preferred embodiments, the compositions comprise from about 0.0001 to about 20%, from about 0.001 to about 10%, from about 0.01 to about 5%, from about 0.1 to about 5%, or from about 0.2 to about 2% Includes extracts of wood from Pauluniatomentosa. In certain other preferred embodiments, the compositions comprise from about 0% to about 1%, from about 0.0001% to about 1%, from about 0.001% to about 1%, or from about 0.01% to about 1% of a fullerenine or fullerene Wood extracts. In certain other preferred embodiments, the compositions comprise from about 1% to about 5%, preferably from about 2% to about 5%, of a paurounin or a Pauluniatomentosa wood extract.

Any suitable carrier may be used in the compositions of the present invention. Preferably, for skin care compositions, the carrier is a cosmetically-acceptable carrier. As will be appreciated by those skilled in the art, cosmetic-acceptable carriers are used in contact with the skin for body, especially skin whitening applications, without undue toxicity, incompatibility, instability, irritation, Suitable carriers include. A safe and effective amount of the carrier is from about 50% to about 99.999%, preferably from about 80% to about 99.9%, more preferably from about 99.9% to about 95%, most preferably from about 99.9% 99.8% to about 98%. The carrier may exist in various forms. For example, emulsion carriers including, but not limited to, water-in-oil, water-in-oil, water-in-oil heavy water and heavy silicone oil heavy oil emulsions are useful in the present invention. Such emulsions may include, for example, a wide range of viscosities from about 100 cp to about 200,000 cp. Examples of suitable carriers which are acceptable for cosmetics include cosmetically acceptable solutions and solutions for cosmetics, suspensions, lotions, creams, serums, essences, gels, toners, sticks, sprays, ointments, liquid wash and soap bars, Shampoo, hair conditioner, paste, foam, mousse, powder, shaving cream, wipe, patch, strip, powdered patch, micro needle patch, bandage, hydrogel, film forming product, facial and skin mask, makeup, liquid drop And so on. Such product types may contain various types of cosmetically-acceptable carriers including, but not limited to, solutions, suspensions, emulsions such as microemulsions and nanoemulsions, gels, solids, liposomes, other encapsulation techniques and the like. The following are non-limiting examples of such carriers. Other carriers may be formulated by those skilled in the art.

In one embodiment, the carrier contains water. In a further embodiment, the carrier may also contain one or more aqueous or organic solvents. Examples of organic solvents include dimethyl isosorbide; Isopropyl myristate; Cationic, anionic and nonionic surfactants; Vegetable oil; Mineral oil; Wax; sword; Synthetic and natural gelling agents; Alkanol; Glycol; And polyols, but are not limited thereto. Examples of glycols include glycerin, propylene glycol, butylene glycol, pentalene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, capryl glycol, glycerol, butanediol and hexanetriol, And copolymers or mixtures thereof. Examples of alkanols include those having from about 2 carbon atoms to about 12 carbon atoms (e.g., from about 2 carbon atoms to about 4 carbon atoms), such as, for example, isopropanol and ethanol, It does not. Examples of polyols include, but are not limited to, those having from about 2 carbon atoms to about 15 carbon atoms (e.g., from about 2 carbon atoms to about 10 carbon atoms), for example, propylene glycol. The organic solvent may be present in the carrier in an amount of from about 1% to about 99.99% (e.g., from about 20% to about 50%) based on the total weight of the carrier. Water may be present in the carrier (before use) in an amount from about 5% to about 95% (e.g., from about 50% to about 90%) based on the total weight of the carrier. The solution may contain any suitable amount of solvent, including from about 40 to about 99.99%. Certain preferred solutions contain from about 50 to about 99.9%, from about 60 to about 99%, from about 70 to about 99%, from about 80 to about 99%, or from about 90 to 99%.

Lotions may be prepared from such solutions. Lotions typically contain at least one softening agent in addition to the solvent. The lotion may contain from about 1% to about 20% (e.g., from about 5% to about 10%) of the softener (s) and from about 50% to about 90% (e.g., from about 60% to about 80% . &Lt; / RTI &gt;

Another type of product that can be formulated from solution is cream. The cream typically contains from about 5% to about 50% (e.g., from about 10% to about 20%) of softener (s) and from about 45% to about 85% (e.g., from about 50% to about 75% Of water.

Another type of product that can be formulated from solutions is ointments. Ointment may contain a simple base of animal, vegetable or synthetic oils or semi-solid hydrocarbons. The ointments may contain from about 2% to about 10% softener (s) plus from about 0.1% to about 2% thickener (s).

Compositions useful in the present invention may also be formulated into emulsions. When the carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier contains the emulsifier (s). The emulsifier may be non-ionic, anionic or cationic.

Lotions and creams may be formulated as emulsions. Typically, such lotions contain from 0.5% to about 5% emulsifier (s), while such creams typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of softener (field); From about 20% to about 80% (e.g., from 30% to about 70%) water; And from about 1% to about 10% (e.g., from about 2% to about 5%) of the emulsifier (s).

Single emulsion skin care preparations, such as lotions and creams of the oil-in-water type and water-in-oil type, are well known in the art and are useful in the present invention. Multiphase emulsion compositions such as water-in-oil heavy water type or water-in-oil type heavy oil types are also useful in the present invention. Generally, such single or multiphasic emulsions contain water, a softener, and an emulsifier as essential components.

The compositions of the present invention may also be formulated as a gel (e. G., Using a suitable gelling agent (s)

Alcohol, alcohol / water, or oil gel). Suitable gelling agents for aqueous and / or alcoholic gels include, but are not limited to, natural rubber, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethylcellulose and hydroxypropylcellulose). Suitable gelling agents for oils (such as mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain from about 0.1% to 5% by weight of such gelling agents.

The compositions of the present invention may also be formulated into solid formulations (e.g., wax-based sticks, soap compositions, powders or wipes). The compositions of the present invention may also be combined with solid, semi-solid or soluble substrates (e.g., wipes, masks, pads, gloves or strips).

In addition, the composition of the present invention can be formulated into a formulation for oral use, for example, a cream toothpaste, a gel, a rinse, a solution, a patch, and the like. The compositions may also be formulated in the form of solutions, emulsions or suspensions for use in the eye, for example in drops or washings, or in the form of solutions, emulsions or suspensions in the vaginal mucosa, such as through gels, lotions, May be formulated for use.

The compositions of the present invention may further comprise any of a variety of additional cosmetic actives. Examples of suitable additional active agents include, but are not limited to, additional skin lightening agents, darkening agents, additional antioxidants, tropoelastin promoters, collagen promoters, anti acne agents, gloss control agents, antimicrobial agents such as antifungal agents, , Anti-parasitic agents, external analgesics, sunscreens, light blockers, antioxidants, keratolytic agents, detergents / surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, astringents, deodorants, depilatories, hair growth enhancers, An anti-inflammatory agent, a firming agent, a moisturizing booster, an effect booster, an anti-callous agent, a skin conditioner, an anti-cellulite agent, a fluoride, a tooth whitening agent, , Such as odor masking agents or pH modifiers. Examples of various suitable additional cosmetically acceptable excipients include, but are not limited to, hydroxy acids, benzoyl peroxide, D-panthenol, UV filters such as Avobenzone (Parsol 1789), Bisdysulfuric acid disodium (Neo Heliopan) AP), diethylaminohydroxybenzoylhexylbenzoate (Uvinul A Plus), eicam (Mexoryl SX), methyl anthranilate, 4-aminobenzoic acid (PABA ), Cyanoate, ethylhexyl triazone (Uvinul T 150), homosalate, 4-methylbenzylidene camphor (Parsol 5000), octyl methoxycinnamate (octinoxate) Octal salicylate (octisalate), fadimate O (Escalol 507), phenylbenzimidazole sulfonic acid (Ensulizole), polysilicon-15 (Farschol SLX), troll Lamin salicylate, beomotrienol (tino (Tinosorb S), Benzophenone 1-12, Dioxybenzone, Drometrazole trisiloxane (Mexoryl XL), Iscotriaisinol (Uvasorb HEB), Octocrylene, Oxibenzone Titanium oxide, zinc oxide, carotenoids, free radical scavengers, spin traps, retinoids and retinoid precursors, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, Such as retinol, retinoic acid and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogens, steroids such as hydrocortisone, 2-dimethylaminoethanol, Copper, copper-containing peptides such as Cu: Gly-His-Lys, coenzyme Q10, amino acids such as proline, vitamin, lactobionic acid, acetyl-coenzyme A, niacin, riboflavin, , Electron transport materials such as NADH and FADH2, and other botanical extracts such as oats, aloe vera, white summer fries, beans, mushroom extracts, and derivatives and mixtures thereof It is not.

In certain preferred embodiments, the composition of the present invention is a skin care composition comprising an extract of fullerene and / or fullerenitomentosa wood and at least one additional skin lightening activator. Examples of suitable additional skin lightening actives include, but are not limited to, tyrosinase inhibitors, melanosomal inhibitors, melanosomal inhibitors including PAR-2 antagonists, exfoliants, sunscreens, retinoids, antioxidants, Sodium benzoate, necanoic acid cetyl ester hydrochloride, skin bleach, linoleic acid, adenosine monophosphate disodium salt, Chamomilla extract, allantoin, opacifiers, talc and silica, zinc salts, etc., and Solano et al. Pigment Cell Res. 19 (550-571) and Ando et al. Int J Mol Sci 11 (2566-2575).

Examples of suitable tyrosinase inhibitors include vitamin C and its derivatives, vitamin E and its derivatives, kojic acid, arbutin, resorcinol, hydroquinone, flavone such as licorice flavonoid, licorice root extract, Mulberry root extract, Dioscorea Coposita root extract, Saxifraga extract, and the like, such as ellagic acid, salicylate and derivatives, glucosamine and derivatives, fullerene, hinokitiol, (4-hydroxyphenyl) -2-butanol (4-HPB), acetylglucosamine, 5,5'-dipropyl-biphenyl-2,2'-diol (Magnolignan) And combinations thereof, but are not limited thereto. Examples of vitamin C derivatives include, but are not limited to, ascorbic acid and its salts, ascorbic acid-2-glucoside, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and vitamin C-enriched natural extracts. Examples of vitamin E derivatives include alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, Their mixtures, natural extracts rich in tocopherol acetate, tocopherol phosphate and vitamin E derivatives. Examples of resorcinol derivatives include resorcinol, 4-substituted resorcinols such as 4-alkyl resorcinol such as 4-butyresorcinol (Lucinol), 4-hexylresor (Synovea HR, Sytheon), phenylethyl resorcinol (Symwhite, Symrise), 1- (2,4-dihydroxyphenyl) - But are not limited to, 3- (2,4-dimethoxy-3-methylphenyl) -propane (nibitol, Unigen) and natural extracts rich in resorcinol. Examples of salicylates include, but are not limited to, 4-methoxypivalic salicylate, salicylic acid, acetylsalicylic acid, 4-methoxysalicylic acid and salts thereof. In certain preferred embodiments, the tyrosinase inhibitor comprises a 4-substituted resorcinol, a vitamin C derivative, or a vitamin E derivative. In a more preferred embodiment, the tyrosinase inhibitor includes phenylethyl resorcinol, 4-hexyl resorcinol, or ascorbyl-2-glucoside.

Examples of suitable melanin-cleaving agents include, but are not limited to, peroxides and enzymes such as peroxidase and ligninase. In certain preferred embodiments, the melanin-inhibiting agent includes peroxides or ligninases.

Examples of suitable melanosome prior inhibitors include PAR-2 antagonists such as soybean trypsin inhibitor or Bowman-Birk inhibitor, vitamin B3 and derivatives such as niacinamide, essential soy, (Whole Soy) and soybean extract. In certain preferred embodiments, the pre-melanosome inhibitor comprises soybean extract or niacinamide.

Exemplary peeling agents include alpha-hydroxy acids such as lactic acid, glycolic acid, malic acid, tartaric acid, citric acid, or any combination of any of the foregoing, beta-hydroxy acids such as salicylic acid, polyhydroxy acids such as lactobion But are not limited to, acids and gluconic acids, and mechanical peels, such as micro peels. In certain preferred embodiments, the peeling agent includes glycolic acid or salicylic acid.

Examples of sunscreens include, but are not limited to, Avobenzone (Forsol 1789), Bisdysulfuric acid disodium (Neo Heliopan AP), Diethylaminohydroxybenzoylhexylbenzoate (Uvinul A Plus), Ecscarm (Mexoryl SX) (Poval 5000), octyl methoxycinnamate (&lt; RTI ID = 0.0 &gt; (4-aminobenzoyl) &lt; / RTI & Octyloxate), octyl salicylate (octisalate), fadimate O (escalol 507), phenylbenzimidazole sulfonic acid (endosylol), polysilicon-15 (parthol SLX), trollamine salicylate , Benzo triison (thinosorb) S, benzophenone 1-12, dioxybenzone, drometrazole trisiloxane (Mexoryl XL), isocotriazinol (ubasorb HEB), octocrylene, oxybenzone (Eusolex 4360), Sullivan Zinoxitriazole (Tinosorb M), titanium dioxide, zinc oxide, and the like.

Examples of retinoids include retinol (vitamin A alcohol), retinal (vitamin A aldehyde), retinyl acetate, retinyl propionate, retinyl linoleate, retinoic acid, retinyl palmitate, isotretinoin, tazarotene, Bexarotene, adapalene, combinations of two of these, and the like. In certain preferred embodiments, the retinoid is selected from the group consisting of retinol, retinal, retinyl acetate, retinyl propionate, retinyl linoleate, and a combination of two of these. In certain more preferred embodiments, the retinoid is retinol.

Examples of antioxidants include water soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine, glutathione), lipoic acid and dihydro lipoic acid, stilbenoids such as resveratrol and Derivatives thereof, lactoferrin, iron and copper chelating agents, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl-2-glucoside, ascorbyl palmitate and ascorbyl polypeptide). Usable antioxidants suitable for use in the compositions of the present invention include butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (such as tocopherol acetate), tocotrienols, and ubiquinone But are not limited thereto. Natural extracts containing antioxidants suitable for use in the compositions of the present invention include extracts containing flavonoids and isoflavonoids and derivatives thereof (e.g., genistein and diadjine), extracts containing resveratrol, and the like , But is not limited thereto. Examples of such natural extracts include grape seed, green tea, black tea, white tea, pine bark, Feverfew, parthenolide free Feverfu, oat extract, blackberry extract, cotinus extract, , Pomelo extract, malt extract, Hesperedin, Grape extract, Portulaca extract, ricocalcone, chalcone, 2,2'-dihydroxychalcone, Primula, Extracts, propolis, and the like.

Additional cosmetic active agents can be present in any suitable amount, for example, from about 0.0001% to about 20%, such as from about 0.001% to about 10%, such as from about 0.01% to about 10% To about 5% by weight of the composition. Is present in an amount of 0.1% to 5% in certain preferred embodiments, and 1% to 2% in another preferred embodiment.

In certain preferred embodiments, the composition of the present invention is a skin care composition comprising an extract of fullerenine and / or fullerenitomotosa wood and at least one additional anti-inflammatory agent. Suitable additional antiinflammatory agents include, but are not limited to, compounds having an IC50 (concentration at which the compound achieves a 50% inhibition of inflammation) of less than or equal to 100 占 퐂 / ml against interleukin-2 in the antiinflammatory assay described below. In a preferred embodiment, the IC 50 of the second anti-inflammatory compound is less than about 70 μg / ml, more preferably less than about 50 μg / ml, more preferably less than about 40 μg / ml, more preferably about 30 μg / ml.

The anti-inflammatory assay evaluates the ability of the agent to reduce the production of cytokines by human lymphocytes stimulated by the T-cell receptor (TCR) activator phytohemagglutinin (PHA), which is done in the following manner. Human leukocytes were collected from leukopheresis from healthy adult males and cultured in 1 x 10 &lt; ⁶ &gt; cells in serum-free lymphocyte growth medium (ExVivo-15, Biowhittaker, Walkersville, Maryland) Lt; / RTI &gt; cells / mL. PBL is stimulated with 10 [mu] g / mL of PHA in the presence or absence of test samples according to published methods (Hamamoto Y., et al. Exp Dermatol 2: 231-235, 1993). After incubation at 37 占 폚, 5% CO ₂ for 48 hours, the supernatant is removed and evaluated for cytokine content using a commercially available multiple cytokine detection kit.

Examples of suitable anti-inflammatory agents include substituted resorcinols, (E) -3- (4-methylphenylsulfonyl) -2-propenenitrile (e.g., "Bay 11-7082" Available from Sigma-Aldrich), tetrahydrocurcuminoids (such as tetrahydrocurcuminoid CG, available from Sabinsa Corporation, Piscataway, NJ), &lt; RTI ID = 0.0 & And extracts and materials derived from:

Phellodendron Amurense Cortex Extract (PCE)

Non-modified soybean (Glycine max)

Fever pew (Tanacetum parthenium)

Ginger (Zingiber officinale)

Bank (Ginko Biloba)

Madecasoides (Centella asiatica extract component)

Cotinus (Cotinus coggygria)

Waste extract (Petasites hybridus)

Gugija (Lycium barbarum)

Milk thistle extract (Silybum marianum)

Rhinoceros japonica (Lonicera japonica)

Basalm of Peru (Myroxylon pereirae)

Sage (Salvia officinalis)

Cranberry extract (Vaccinium oxycoccos)

Amaranthus (Amaranthus cruentus)

Pomegranate (Punica granatum)

Yervemate (Ilex paraguariensis leaf extract)

White Lily flower extract (Lilium Candidum)

Olive leaf extract (Olea europaea)

Floretin (apple extract)

Oat flour (Aveena Sativa)

Liphenol (Hop: Humulus lupulus) Extract

Bugrane P (Ononis spinosa)

Ricoh chalcone (licorice: Glycyrrhiza inflate extract component)

Symrelief (Visavol and ginger extract)

A combination of two or more of these.

Resorcinol is a dihydroxyphenol compound (i.e., 1,3 dihydroxybenzene) having the structure:

As used herein, "substituted resorcinol" means a resorcinol comprising at least one substituent at the 2, 4, 5, or 6 position. Thus, substituted resorcinols may have from 1 to 4 substituents. As indicated above, position 1 and position 3 of the substituted resorcinol comprise an -OH group.

When substituted LES sorbitan the embodiment used for the play an anti-inflammatory, it is highly preferred that all the substituents of the substituted resorcinol are free phenyl (-C ₆ H ₅ aromatic) part. In certain embodiments, all substituents have no aromatic moiety (with or without heteroatoms). In certain such embodiments, it is preferred that all substituents of the substituted resorcinol have no ketone functionality (carbonyl attached to two other carbon atoms). In certain other such embodiments, not all of the substituents of the substituted resorcinol have both phenyl and ketone functionalities. In certain other such embodiments, the substituted resorcinol has 5 to 11 carbon atoms, preferably 5 to 10 carbon atoms, more preferably 5 to 9 carbon atoms, most preferably 5 to 8 carbon atoms At least one substituent comprising a carbon atom. In certain other such embodiments, at least one of the substituents includes an alkyl group such as having the number of carbon atoms described above. The alkyl group is preferably unsaturated.

In certain embodiments, the 4 position of resorcinol is substituted, and in certain embodiments, only 4 positions are substituted. In another embodiment, the 4-position is substituted with an alkyl group. In certain preferred embodiments, the substituted resorcinol comprises a single substituent at the 4-position, including an alkyl group. In certain other preferred embodiments, the substituted resorcinol comprises a single substituent at the 4 position, consisting of an alkyl group directly attached to the benzene ring.

Particularly suitable resorcinols for anti-inflammatory agents include 4-hexyl resorcinol and 4-octyl resorcinol, especially 4-hexyl resorcinol. The structures of 4-hexylresorcinol and 4-octylisosorbanol are shown below:

４-헥실 레소르시놀

4-hexylresorcinol

４-옥틸레소르시놀

4-octylsorbicinol

4-Hexylresorcinol is available from SYTheon, Lincoln Park, New Jersey, USA, as " SYNOVEA HR ". 4-Octylresorcinol is commercially available from City Chemical LLC, West Haven, Conn.

In certain embodiments, the substituted resorcinol comprises at least two substituents at the 2, 4, 5, or 6 position. Such substituents may optionally be connected to form a cyclic aliphatic hydrocarbon optionally containing a heteroatom such as a ring, e.g., sulfur or oxygen. Such linked substituents may contain from 5 to 10 carbon atoms, for example, from 8 to 10 carbon atoms, and optionally contain from 1 to 3 heteroatoms. Examples of suitable substituted resorcinols including cyclic aliphatic substituents that combine positions 2 and 3 include zearalanone and beta -zearalanol:

제아랄라논(Zearalanone)

Zearalanone

β-제아랄라놀(Zearalanol)

beta -zearalanol (Zearalanol)

Aralanol and beta -earalanol are commercially available from Sigma Chemicals, St. Louis, Missouri, USA.

In certain other embodiments, the substituted resorcinol comprises halide-containing and / or nitroso-containing substituents. A suitable example contains -Cl or -N = O directly bonded to the benzene ring. These substituents may be present, for example, at positions 2 and 4, 2 and 6, or 4 and 6. An example of a dihalide-substituted resorcinol is 2,6-dichlororesorcinol. An example of a dinitroso-substituted resorcinol is 2,4-dinitrososoricone:

２，４-다이니트로소소르시놀

2,4-dinitroso sorsinol

2,6-Dichlororesorcinol and 2,4-Dinitrososorcinol are available from City Chemicals, LLC, West Haven, Conn., USA.

The substituted resorcinols are prepared by means known in the art, for example, using the techniques described in U.S. Patent No. 4,337,370, the entirety of which is incorporated herein by reference.

Substituted resorcinols may have any suitable molecular weight. In certain embodiments, the molecular weight range of the substituted resorcinol is from about 175 to about 300.

"Extract of Fibber Pew" is a product containing a phthalonolipid-free active ingredient from Fibberfu (Tannacusum papernium) and a process for its production. (PARTHENOLIDE FREE BIOACTIVE INGREDIENTS FROM FEVERFEW (TANACETUM PARTHENIUM) AND PROCESSES FOR THEIR PRODUCTION &Lt; / RTI &gt; of the plant "Tanacettum parterenum &quot;, which may be prepared according to the details disclosed in U.S. Patent Publication No. 2007/0196523. One particularly suitable FIBERPUEY extract is commercially available from Integrated Botanical Technologies, Inc., Osing, NY, as about 20% active FIBERPU.

The compositions of the present invention may comprise one or more additional anti-inflammatory compounds in an amount effective for cosmetics. The composition preferably comprises from about 0.1% to about 10%, more preferably from about 0.5% to about 5%, of an additional anti-inflammatory compound on an active water basis.

In the composition of the present invention, the concentration ratio of the folowinin and / or the pawlonia tautentosa wood extract to the additional anti-inflammatory compound may vary. For example, the extract and the anti-inflammatory compound have a concentration ratio on a weight basis of from about 0.001 to about 100, preferably from about 0.01 to about 10, more preferably from about 0.25 to about 2, Determined by dividing the weight-based concentration by the weight-based concentration of the additional anti-inflammatory compound).

In certain preferred embodiments, the composition of the present invention is a skin care composition comprising an extract of folowinin and / or paulonia topomonta wood and at least one additional agent to improve the signs of aging. Examples of suitable additional agents for improving the signs of aging include tropoelastin promoters, collagen promoters, retinoids, hyaluronic acid, dimethylaminoethanol, N, N, N ', N'-tetrakis (2- hydroxypropyl) ethylene diamine Polyhydroxy acids, and combinations of two or more thereof, but are not limited thereto.

As used herein, "tropoelastin promoter" refers to a class of compounds having biological activity that enhance the production of tropoelastin. The tropoelastin promoter according to the present invention includes all natural or synthetic compounds capable of enhancing the production of tropoelastin in the human body.

Suitable tropoelastin promoters can be determined, for example, using tropoelastin promoter assays. Analysis of the tropoelastin promoter is carried out as follows. Rat cardiac muscle cell H9C2 (e.g., available from ATCC, Manassas, Va.) Is used. Supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units / ml penicillin, and 50 ug / ml streptomycin (Invitrogen Life Technologies, Carlsbad, CA) The culture is maintained in medium (DMEM, Invitrogen Life Technologies, Carlsbad, CA). Elastin promoter-Luciferase reporter construct (Elp2.2, a 2.2 kb elastin promoter fragment from nt-2267 to nt + 2, which is available from Promega, Madison, Wis., Which drives the firefly luciferase gene) To transiently transfect cell cultures. The DNA is prepared by a Qiagen Maxi column (Qiagen, Valencia, Calif.). In all transfections, constructs with the tamilidine kinase promoter and the Renilla luciferase reporter gene (pRL-TK, Promega, Madison, Wis.) Were included as internal controls. Typically, cells grown in 48 well plates are transfected with 0.45 占 퐂 of total DNA per well using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA). After 1 day of transfection, cells were treated with the indicated concentrations of the agent for approximately 24 hours, and then the Dual-Luciferase Reporter System from Promega (Madison, Wisconsin, USA), according to the manufacturer's protocol, 0.0 &gt; luciferase &lt; / RTI &gt; assay. First, firefly luciferase activity (indicating the activity of elastin promoter) was first measured using a luminescence meter LMAX from Molecular Devices (Sunnyvale, CA) and then with Renilla luciferase (internal control) . The ratio of the two activities of luciferase activity (RLU) is used to evaluate tropoelastin promoter activity. Preferably, the tropoelastin promoter is administered at a concentration of at least one of a range of 0.5 micrograms / milliliter to 2.5 milligrams / milliliter (based on active), and preferably 1.0 microgram / milliliter to 2.5 At least one concentration of the range of milligrams / milliliter (based on active), the activity of the tropoelastin promoter is at least 1.1, preferably at least 1.25, more preferably at least 1.3, and most preferably, At least 1.5.

Examples of suitable tropoelastin promoting agents include, but are not limited to, blackberry extract, cotinus extract, Feverfew extract, Phyllanthus niruri extract, and bimetallic complexes with copper and / or zinc constituents . The bimetallic complexes having the copper and / or zinc constituents include, for example, copper-zinc citrate, copper-zinc oxalate, copper-zinc tartrate, copper-zinc malate, copper-zinc succinate, Zinc glutamate, copper-zinc glutarate, copper-zinc fumarate, copper-zinc glucarate, copper-zinc polyacrylic acid, copper-zinc glutamate, copper- Adipate, copper-zinc pimelate, copper-zinc suverate, copper-zinc azilate, copper-zinc sebacate, copper-zinc dodecanoate, or combinations thereof. In a preferred embodiment, the tropoelastin promoting agent is selected from a blackberry extract, a cotinus extract, a fiver extract, and combinations thereof. In a particularly preferred embodiment, the tropoelastin promoting agent is selected from blackberry extract, Fibberis extract, and combinations thereof.

"Fog tree extract" means an extract of a leaf of "Cotinus corgi ghia ", for example, its water extract - available from Bilkokoop, Sofia, Bulgaria. "Blackberry extract" means a blend of compounds isolated from a plant of the genus Rubus, preferably Rubus fruticosus. In one embodiment, the compound is isolated from a plant flower. In a further embodiment, the compound is isolated from the dried flower of the plant. Such compounds may be isolated from one or more parts of the plant (e.g., whole plants, plant flowers, seeds, roots, rhizomes, stems, fruits and / or leaves). In a preferred embodiment, the blackberry extract is a blackberry leaf extract.

The extraction process may include physically peeling off such pieces of the plant and, for example, milling it. Additional extraction of suitable compounds may also be carried out using extraction procedures well known in the art (e. G., Organic solvents such as lower C 1 -C 8 alcohols, C 1 -C 8 alkyl polyols, C 1 -C 8 alkyl ketones, C 1 -C 8 alkyl ethers, And the use of inorganic solvents such as water, inorganic acids such as hydrochloric acid, and inorganic bases such as sodium hydroxide).

For example, the Blackberry leaf extract may be prepared by extraction with water, alcohol, such as ethanol, or a combination thereof, as a solvent. However, an extract prepared using a solvent containing both ethanol and water is preferred. The blackberry leaves are preferably dried prior to extraction. It is also preferable to use only the leaves of the blackberry plants for extraction, and it is preferable not to use other plant parts, for example, berries of the blackberry or its branches and roots. In one embodiment, the extraction process for the production of blackberry leaf extract comprises the following steps: a) adding a solvent containing an alcohol selected from the group consisting of methanol, ethanol, n-propanol, isopropanol to the blackberry leaf B) extracting the blackberry leaves for up to 72 hours using a solvent.

Detailed procedures for preparing suitable blackberry leaf extracts are disclosed in United States Patent Application Publication 2008/0095719, the disclosure of which is incorporated herein by reference in its entirety. One particularly suitable blackberry extract is prepared by extracting the leaves of Lubus fructus corus with a mixture of water and ethanol and is blended with the maltodextrin matrix at about 5% to about 10% activity, Quot; Symrise Inc. " and sold under the name "SymMatrix &quot;.

The extract of "pilatus niluri" can be harvested and used as whole plants, or alternatively, one or more parts of plants (e.g., flowers, seeds, roots, rhizomes, stems, Can be used. The Pilot's nururi plant or parts thereof can be finely divided into powders by, for example, milling or milling. A suitable milled form of Philantus nururi is available from Raintree Nutrition, Inc. of Carson City, Nev. Preferably, a low molecular weight fragment of Pylontus niluri, for example, a fragment of Pylontus niluri substantially free of molecular species having a molecular weight greater than about 100,000 daltons, is used. Preferably, such low molecular weight fragments are water extractable from a Pilot's nurri plant.

The compositions of the present invention may comprise a cosmetically effective amount of one or more tropoelastin promoters, such as those described above. The composition preferably comprises, based on the active agent, from about 0.1% to about 10% tropoelastin promoter, more preferably from about 0.5% to about 5% tropoelastin promoter, most preferably from about 0.5 % &Lt; / RTI &gt; to about 2% tropoelastin promoting agent.

As used herein, "collagen promoter" refers to a compound having biological activity that enhances the production of collagen. According to the present invention, "non-retinoid collagen promoter" includes all natural or synthetic compounds that are not retinoids or are derived from retinoids and that can enhance the production of collagen in the human body.

Suitable collagen promoters can be determined, for example, using a collagen promoter assay (COLLAGEN PROMOTER ASSAY). Analysis of the collagen promoter is carried out as follows. The rat heart muscle cell H9C2, which may be purchased from ATCC (Manassas, Va.), Is used. Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units / mL penicillin, and 50 ug / mL streptomycin (Invitrogen Life Technologies, Carlsbad, CA) (DMEM, Invitrogen Life Technologies, Carlsbad, CA). For example, PREMAS Biotechnology. The cell culture is transiently transfected using the Collagen 1A promoter-luciferase reporter construct, which is available from PREMAS Biotech Pvt. Ltd (Hariana, India), which drives the firefly luciferase gene do. In all transfections, constructs with tamilidine kinase promoter and Renilla luciferase reporter gene (pRL-TK, Promega, Madison, Wis.) Were included as internal controls. Cells grown in 48 well plates are transfected with 0.45 [mu] g total DNA per well using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA). After 1 day of transfection, cells were treated with the indicated concentrations of the agent for approximately 24 hours, and then the Dual-Luciferase Reporter System from Promega (Madison, Wisconsin, USA), according to the manufacturer's protocol, 0.0 &gt; luciferase &lt; / RTI &gt; assay. Using the luminescence meter Lemax from Molecular Devices (Sunnyvale, CA), firefly luciferase activity (indicative of collagen promoter activity) was measured first, followed by measurement of Renilla luciferase (internal control) do. The ratio of the two luciferase activities (RLU) is used to evaluate the activity of each promoter.

Suitable collagen promoters are preferably present at a concentration of at least one of the ranges of 0.5 micrograms / milliliter to 2.5 milligrams / milliliter (based on active), preferably 1.0 microgram / milliliter to 2.5 milligrams / Milliliter (based on active material), the collagen promoter activity is 1.2 or more, preferably 1.25 or more, and more preferably 1.3 or more. Examples of suitable non-retinoid collagen enhancers include, but are not limited to, an extract of Feverfew (Tanacettum parterenum), an extract of Centella asiatica, an extract of Siegesbeckia orientalis; Extract of soybean; Collagen promoting peptide; Uronic acid; And Asian ticoside.

On the island of Reunion there are Violette marronne, Gotu Kola or Indian pennywort in India, Centella repanda in North America and Talapetraka in Madagascar. , Is a polymorphous herb and belongs to Umbelliferae (Apiaceae), and in particular belongs to the Hydrocotyle subspecies. It grows wild throughout the tropics and prefers wet and shaded areas of about 600 to 1200 meters above sea level. Centella asiatica has three varieties: Typica, Abyssinica and Floridana. This herb is known and used for its healing, sedation, analgesic, antidepressant, antiviral and antimicrobial properties. The biological activity of this herb is believed to be due to the presence of triterpene molecules in the herb. Suitable Centella asiatica extracts are available from Bayer Consumer Healthcare of Basel, Switzerland as TECA.

"Extracts of Svecksia orientalis" refers to the extracts of Sederma (Darutoside, available from Croda International Group, Edison, NJ, USA) Refers to any of a variety of extracts of Becky A Orientalis.

Suitable collagen-promoting peptides include: (1) palmitoylpentapeptides, especially Pal-Lys-Thr-1, which is available from Cedar (Croda International Group, Edison, NJ) as MATRIXYL, Matrikine peptides (i. E., Extracellular matrix proteins - peptides derived from degradation of collagen, elastin, or proteoglycans), including Thr-Lys-Ser-OH; (2) GHK copper peptides available from Photomedex, Montgomeryville, Pa., As PROCYTE; (3) palmitoyl GHK peptides, commercially available as Biopoeptide CL from Sedma (Croda International Group, Edison, NJ); (4) Peptides VFTRN, TRNDKL or cosmetically acceptable salts thereof, as described in EP 1775306 B1 and described in the following formulas I, II and III:

(I)

Wherein &lt; RTI ID = 0.0 &gt; formula I &lt; / RTI &gt; contains at least 6 amino acid residues;

A1 is Val, Ala, Leu, Met or absent;

A2 is Arg, Lys or absent;

A3 is Phe, Tyr or absent;

A4 is Thr, Ser, Ala, or Lys;

A5 is Arg or Lys;

A6 is Asn, Asp, Gly, or Gln;

A7 is Asp, Asn, GIu or absent;

A8 is Lys, Arg or absent;

A9 is Leu, Met, Val, Ile, Phe or absent;

However, A3 can only be absent if A2 is absent, A2 can only be absent if A1 is absent, A7 can be absent only when A8 is absent, A8 is absent if A9 is absent I can only; Each R1 and R2 is independently H, C1-12 alkyl, C7-10 phenylalkyl, or C (= O) E1, wherein E1 is C1-12alkyl, C3-14alkenyl, C3-14 Alkynyl, phenyl, 3,4-dihydroxyphenylalkyl, naphthyl, or C7-10 phenylalkyl; With the proviso that when either R1 or R2 is C (= O) El, the other should be H; R3 is OH, NH2, C1-12 alkoxy, C7-10 phenylalkoxy, C11-14 naphthylalkoxy, C1-12 alkylamino, C7-10 phenylalkylamino, or C11-14 naphthylalkylamino)

&Lt; RTI ID = 0.0 &

RTI ID = 0.0 &gt; (II) &lt; / RTI &gt; contains at least 6 amino acid residues;

A &apos; is Val, Ala, Leu or Met;

A &apos; 2 is Arg or Lys;

A'3 is Phe or Tyr;

A'4 is Leu, Met, Val, Ile or Phe;

A &apos; 5 is His, Tyr or Phe;

A &apos; 6 is Ser, Thr, Ala or Lys;

A &apos; 7 is Tyr or Phe;

A &apos; 8 is Asp, Asn or GIu;

A'9 is Leu, Met, Val, Ile or Phe;

A &apos; 10 is Lys or Arg;

A'11 is Asn, Asp, Gly or Gln;

R1, R2, and R3 are the same as defined in formula (I)

(III)

(III) &lt; / RTI &gt; contains at least 6 amino acid residues;

A "1 is Cys or Ser;

A "2 is His, Tyr or Phe;

A "3 is Lys or Arg;

A "4 is Leu, Met, Val, Ile or Phe;

A "5 is Leu, Met, Val, Ile or Phe;

A "6 is His, Tyr or Phe;

A "7 is Asn, Asp, Gly or Gln;

A "8 is Val, Ala, Leu or Met;

A "9 is Asn, Asp, Gly or Gln;

A "10 is Lys or Arg;

R1, R2, and R3 are the same as defined in formula (I)

(5) biomimetic tetrapeptides such as those available as Chronoline Tri Peptide from Unipex, of Quebec, Canada; And

(6) Palmitoyl tripeptides available from Syn-Coll, DSM, Basel, Switzerland. Ursolic acid is also known as pentacyltric triterpenic acid, Prunol, Malol, Urson, beta-uric acid and 3-beta-hydroxy-ur-12-en-28- It is known. This is available, for example, from Sigma-Aldrich, St. Louis, Missouri, USA.

Familiale Division Serdex)로부터 구매가능하다.Chemically a mixture of [6 - [[3,4-dihydroxy-6- (hydroxymethyl) -5- (3,4,5-trihydroxy-6-methyloxan- Yl] 10,11-dihydroxy-9- (hydroxymethyl) -1,2,6a, 6b, 9,12a-hexa Methyl-2,3,4,5,6,6a, 7,8,8a, 10,11,12,13,14b-tetradecahydro-1H-pisene-4a-carboxylate) For example, Bayer &lt; RTI ID = 0.0 &gt; Suthefamily &lt; / RTI &gt; Division Cedex 69, Bladard Viktor Hugo 93400,

Familiale Division Serdex).

The compositions of the present invention may comprise one or more collagen promoters in an amount effective for cosmetics. The composition preferably comprises about 0.1% to about 10% collagen enhancer, more preferably about 0.5% to about 5% collagen promoter, and most preferably about 0.5% % &Lt; / RTI &gt; to about 2% collagen promoter.

A variety of other materials may also be present in the compositions of the present invention. In certain preferred embodiments, the composition is a skin care composition comprising one or more substances selected from the group consisting of: a surfactant, a chelating agent, a softener, a humectant, a conditioner, an antiseptic, an opacifying agent,

What the softener means is a compound that helps maintain a smooth, smooth and supple skin appearance (e.g., by remaining on the skin surface or in the horny layer of the skin to act as a lubricant). Examples of suitable emollients are described in [35, pages 399-415 (Skin Feel Agents, by G Zocchi), Handbook of Cosmetic Science and Technology (edited by A. Barel, M. Paye and H. Maibach, Dekker, Inc New York, NY), and include vegetable oils, hexyldecyl stearate, and vegetable oils, nuts and vegetable oils such as macadamia nut oil, rice bran oil, grape seed oil, palm oil, prim rose oil, hydrogenated peanut oil and avocado oil.

What humectant means is a compound (e.g., a hygroscopic compound) intended to increase the moisture content of the upper layer of the skin. Examples of suitable humectants include, but are not limited to, Chapter 35, pages 399-415 (Skin Feel Agents, by G Zocchi), Handbook of Cosmetic Science and Technology (edited by A. Barel, M. Paye and H. Maibach, (Eg, α, α-trehalose, β, β-trehalose, α, β-trehalose) or salts or esters thereof, such as glycerin, sorbitol or trehalose (E. G., Trehalose 6-phosphate). &Lt; / RTI &gt;

By surfactant is meant a surface active agent intended to cleanse or emulsify. Examples of suitable surfactants are described in Chapter 37, pages 431-450 (Classification of surfactants, by L. Oldenhove de Guertechin), Handbook of Cosmetic Science and Technology (edited by A. Barel, M. Paye and H. Maibach, Published in 2001 by Marcel Dekker, Inc New York, NY) and include anionic surfactants such as sulfates, cationic surfactants such as betaine, amphoteric surfactants such as sodium Non-ionic surfactants, such as alkyl polyglucosides, but are not limited thereto.

Examples of suitable chelating agents include those capable of protecting and preserving the compositions of the present invention. Preferably, the chelating agent is ethylenediaminetetraacetic acid ("EDTA"), more preferably tetrasodium EDTA, which is commercially available from the Dow Chemical Company of Midland, Mich. Quot; Versene 100XL ".

Suitable preservatives include, for example, parabens, quaternary ammonium species, phenoxyethanol, benzoates, DMDM hydantoins, organic acids and may contain from about 0% to about 1% or about 0.05% % &Lt; / RTI &gt; to about 0.5% by weight of the composition.

Any of a variety of conditioners that impart additional qualities such as gloss to the hair are suitable for use in the present invention. Examples include, but are not limited to, volatile silicone conditioning agents having an atmospheric pressure boiling point of less than about 220 &lt; 0 &gt; C. Examples of suitable volatile silicones include, but are not limited to, polydimethylsiloxane, polydimethylcyclosiloxane, hexamethyldisiloxane, cyclomethicone fluids, such as those sold by the Dow Corning Corporation of Midland, Mich. Quot; DC-345 "and mixtures thereof, preferably a cyclomethicone fluid. Other suitable conditioners include cationic polymers, which include polyquaternium, cationic guar, and the like.

Any of a variety of commercially available pearlescent or opacifying agents are suitable for use in the present invention. Examples of suitable pearlescent agents or opacifiers include (a) fatty acids having from about 16 to about 22 carbon atoms and (b) mono- or diesters of ethylene or propylene glycol; (a) a fatty acid having from about 16 to about 22 carbon atoms and (b) a fatty acid having the formula HO- (JO) _a- H, wherein J is an alkylene group having about 2 to about 3 carbon atoms; 2 or 3) mono or diesters of polyalkylene glycols; Fatty alcohols containing from about 16 to about 22 carbon atoms; Fatty esters of the formula KCOOCH L ₂ (Here, the K and L independently contain from about 15 to about 21 carbon atoms); Inorganic solids insoluble in the shampoo composition; And mixtures thereof, but are not limited thereto.

Any fragrance composition suitable for use on the skin and desirable for a skin care composition may be used in accordance with the present invention.

In certain preferred embodiments, the present invention can be in the form of a substrate comprising the composition of the present invention. Any suitable substrate may be used in the present invention. Examples of suitable substrate and substrate materials are disclosed, for example, in U.S. Patent Nos. 2005/0226834 and 2009/0241242, all of which are incorporated herein by reference.

In certain preferred embodiments, the substrate is a wipe, glove, or facial mask. Preferably, this embodiment may comprise a water-insoluble substrate as defined in the above references. In certain embodiments, the water-insoluble substrate may have a size and shape to allow it to cover the face of a human user and to make the water-insoluble substrate as a mask substrate easier to place around the user &apos; s face. For example, the water insoluble mask substrate may have openings for the user's mouth, nose, and / or eyes. Alternatively, the water-insoluble substrate may not have such openings. This configuration without openings can be useful in embodiments of the present invention where the water insoluble substrate is intended to cover the skin area rather than the face, or in embodiments of the present invention when the water insoluble substrate is used as a wipe. The water-insoluble substrate may have a variety of shapes, such as angled (e.g., rectangular) or arcuate, such as annular or oval. In certain embodiments, the description is gloves such as those described in U.S. Patent Publication No. 2006/0141014, which is incorporated herein by reference in its entirety.

In one embodiment of the invention, the article comprises a plurality of water-insoluble substrates of different shapes. In one embodiment of the present invention, the article comprises a first water-insoluble substrate and a second water-insoluble substrate. The first water insoluble substrate is shaped for application to the forehead and the second water insoluble substrate is shaped for application to the peripheries of the mouth, such as above and / or below the lips, jaws, and / or cheeks. In one embodiment of the present invention, the first water-insoluble substrate is also applied to the nose region of the face. The first water-insoluble substrate may have a surface area of from about 100 cm ² to about 200 cm ² , such as from about 120 cm ² to about 160 cm ² , and the second water-insoluble substrate has a surface area of from about 100 cm ² to about 300 cm ² , Such as from about 150 cm ² to about 250 cm ² . In one embodiment of the present invention, the water-insoluble substrate has a low stiffness such that it can readily conform to, or cover, for example, the face of a user or other body parts.

In certain embodiments, the methods of the present invention comprise administering to a skin comprising at least about 20% by weight of a paurologic or plant extract, which requires treatment (e. G., Requires improvement of one or more aging indications, etc.) Wherein the extract comprises at least about 20% by weight of fululoinine. In certain more preferred embodiments, the method comprises administering at least about 40% by weight of faurosine, or at least about 40% by weight of faurosine, such as at least about 50% by weight, at least about 60% The method comprising applying a composition comprising a plant extract comprising at least &lt; RTI ID = 0.0 &gt; wt% &lt; / RTI &gt;

In certain embodiments, the methods of the invention comprise applying a composition comprising pawloinin isolated and / or purified to 90% or more of the skin in need of treatment. In certain preferred embodiments, the composition contains or is added to a poultrynin material that is greater than 90% pure pawlunin.

In certain embodiments, a composition comprising isolated fowunin and / or faurolone may be prepared so that essentially no material is present. In one embodiment, the composition comprising the paurounin material, the paurounin material, or both, is essentially free of uric acid, beta-sitosterol, or both.

Preferably, the method of the invention comprises the step of applying to the skin an effective amount, preferably a safe and effective amount of faurolin. In certain preferred embodiments, the method comprises applying greater than 0 to about 20% of the foulunin to the skin of interest. In certain other preferred embodiments, the method comprises administering to a skin in need about 0.0001 to about 20%, about 0.001 to about 10%, about 0.01 to about 5%, about 0.1 to about 5 %, Or about 0.2% to about 2% of the fullerenine. In certain other preferred embodiments, the methods comprise greater than 0 to about 1% of pouloninin to the skin, from about 0.0001 to about 1%, from about 0.001 to about 1%, or from about 0.01 to about 1%. In certain other preferred embodiments, the method comprises applying from about 1% to about 5%, preferably from about 2% to about 5%, of faurologic to the skin.

The present invention further includes a method of lightening skin by applying an extract of Paulununin or Pauluniatomonta wood to the skin requiring skin lightening treatment, wherein the extract and its embodiments are as described above . In certain embodiments, the method comprises applying a composition of the present invention comprising an extract of Paulonin or PauloniatisTomentosa wood to the skin in need of a skin lightening treatment, Lt; / RTI &gt; form.

The present invention may include application to any skin that requires treatment on the body. For example, application to any one or more of the face, the lips, the neck, the chest, the back, the arms, the armpits, the hands, the feet and / or the skin of the legs can be made.

Preferably, the composition of the present invention comprises the step of applying to the skin an effective amount, preferably a safe and effective amount of a pawloinin or a Pauluniatomentosa wood extract effective for skin lightening. In certain preferred embodiments, the method comprises applying to the skin in need of more than 0 to about 20% of a paurounin or a Pauluniatomentosa wood extract. In certain other preferred embodiments, the method comprises administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in an amount of from about 0.0001 to about 20%, from about 0.001 to about 10%, from about 0.01 to about 5%, from about 0.1 to about 5%, or from about 0.2 to about 2% It comprises the step of applying the wood extract of Pauluniatomentosa to the required skin. In certain other preferred embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of more than 0 to about 1%, about 0.0001 to about 1%, about 0.001 to about 1%, or about 0.01 to about 1% And applying the wood extract to the skin. In certain other preferred embodiments, the method comprises applying to the skin from about 1% to about 5%, preferably from about 2% to about 5%, of a paurounin or a Pauluniatomentosa wood extract.

Any suitable method of applying the extract to the required skin may be used in accordance with the present invention. For example, the extract may be applied to the required skin directly from the wrapping paper, to the required skin by hand, or delivered from a substrate such as a wipe or mask or a combination of two or more of these. In another embodiment, the extract may be applied through a dropper, tube, roller, spray, patch, or may be added to a bath or otherwise to be applied to the skin.

In certain embodiments, the method of the present invention further comprises the step of leaving the wood extract of Pauloinin or PaulowniaTomentosa for contact with the skin for a predetermined period of time. For example, in certain preferred embodiments, after application, the extract is left in contact with the skin for at least about 15 minutes. In certain more preferred embodiments, the extract is left in contact with the skin for at least about 20 minutes, more preferably at least about one hour.

In certain embodiments, the method of the present invention comprises a therapy comprising multipotent application of skin extracts of Pauloinin or Pauluniatomentosa to the skin over a selected period of time. For example, in certain embodiments, the present invention provides a method of treating a skin that requires skin lightening for at least 12 weeks, preferably at least 8 weeks, for at least 12 weeks, a composition comprising a pauloinin or a PaulowniaTomentosa wood extract, And more preferably for at least two weeks, once or twice daily.

In certain preferred embodiments, the method of the present invention comprises applying to the skin at least two different compositions or products comprising a wood extract of Pauloinin or PaulowniaTomentosa. For example, the method comprises applying a first composition comprising a wood extract of Paulownia or Pauluniatomentosa to the skin requiring skin lightening followed by a paurolinin or Pauluniatomentosa wood extract Applying the second composition different from the first composition to the skin requiring skin lightening. In certain preferred embodiments, the first and second compositions may be independently selected from the group consisting of lotions, cleansers, masks, wipes, creams, serums, gels, and the like. In certain preferred embodiments, at least one of the first and second compositions is a cleanser, lotion, cream, essence, or serum, and the other is a facial mask or a wipe. In certain other preferred embodiments, at least one of the first and second compositions is a cleanser and the other is a lotion or cream.

In certain other preferred embodiments, the method comprises the step of applying three or more products comprising skin extracts of Pauloinin or Pauluniatomentosa to the skin requiring skin lightening. Preferably, these three products are selected from the group consisting of cleansers, lotions, creams, essences, and facial masks.

The present invention relates to a method for improving skin aging symptoms comprising the step of applying an extract of Pauloinin or Pauloniatomontosa wood to skin requiring improvement of signs of aging, wherein such extracts and compositions are as described above And a method of reducing skin irritation comprising the step of applying to the skin a reduction in skin irritation, wherein the extract is a poulouninin or a Pauluniatomonta wood extract, these extracts and compositions being as described above. .

The present invention may include application to any skin that requires treatment on the body. For example, application to any one or more of the face, the lips, the neck, the chest, the back, the arms, the armpits, the hands, the feet and / or the skin of the legs can be made.

Preferably, the method of the present invention comprises the step of applying a safe and effective amount of a paurolinine or a Paulownia tautentosa wood extract to the skin. In certain preferred embodiments, the method comprises applying to the skin in need of more than 0 to about 20% of a paurounin or a Pauluniatomentosa wood extract. In certain other preferred embodiments, the method comprises administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in an amount of from about 0.0001 to about 20%, from about 0.001 to about 10%, from about 0.01 to about 5%, from about 0.1 to about 5%, or from about 0.2 to about 2% It comprises the step of applying the wood extract of Pauluniatomentosa to the required skin. In certain other preferred embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of more than 0 to about 1%, about 0.0001 to about 1%, about 0.001 to about 1%, or about 0.01 to about 1% And applying the wood extract to the skin. In certain other preferred embodiments, the method comprises applying to the skin from about 1% to about 5%, preferably from about 2% to about 5%, of a paurounin or a Pauluniatomentosa wood extract.

Any suitable method of applying the extract to the required skin may be used in accordance with the present invention. For example, the extract may be applied to the required skin directly from the wrapping paper, to the required skin by hand, or delivered from a substrate such as a wipe or mask or a combination of two or more of these. In another embodiment, the extract may be applied via a dropper, tube, roller spray, patch, or may be added to a bath or otherwise to be applied to the skin.

In certain embodiments, the method of the present invention further comprises the step of leaving the wood extract of Pauloinin or PaulowniaTomentosa for contact with the skin for a predetermined period of time. For example, in certain preferred embodiments, after application, the extract is left in contact with the skin for at least about 15 minutes. In certain more preferred embodiments, the extract is left in contact with the skin for at least about 20 minutes, more preferably at least about one hour.

In certain embodiments, the method of the present invention comprises a therapy comprising multipotent application of skin extracts of Pauloinin or Pauluniatomentosa to the skin over a selected period of time. For example, in certain embodiments, the present invention provides a composition comprising a skin extract of Pauloinin or Pauluniatomonta on the skin for a period of at least 12 weeks, preferably at least 8 weeks, For a period of at least two weeks, once or twice a day.

In certain preferred embodiments, the methods of the present invention comprise applying to the skin at least two different compositions or products comprising a wood extract of Pauloinin or PaulowniaTomentosa. For example, the method may include applying a first composition comprising a wood extract of Paulownia or Pauluniatomonta to a skin in need thereof, then adding to the skin a pawloinin or a Paulunia tautentosa wood extract However, the running may include applying to the skin a second composition that is different from the first composition. In certain preferred embodiments, the first and second compositions may be independently selected from the group consisting of lotions, cleansers, masks, wipes, creams, serums, gels, and the like. In certain preferred embodiments, at least one of the first and second compositions is a cleanser, lotion, cream, essence, or serum, and the other is a facial mask or a wipe. In certain other preferred embodiments, at least one of the first and second compositions is a cleanser and the other is a lotion or cream.

In certain other preferred embodiments, the method comprises the step of applying three or more products comprising faurosine to the skin in need of an aging symptom improvement or other treatment. Preferably, these three products are selected from the group consisting of cleansers, lotions, creams, essences, and facial masks.

The compositions of the present invention may be suitable for a variety of other applications. For example, the compositions of the present invention may be used in the treatment of inflammation including dry skin cleansing and / or moisturizing, aging symptom treatment and / or hyperpigmentation after inflammation, pore size reduction, acne treatment, reduction of sebum production, Reduced appearance, decreased cellulite appearance, or reduced orange peel appearance. In certain other embodiments, the compositions of the present invention may be applied simultaneously with or within a few hours of a mechanical or physical depilatory agent, such as microdermabrasion treatment, or a keratolytic agent or chemical depilator, such as salicylic acid. In certain other embodiments, the compositions of the present invention are applied to mucosal or other tissues, e.g., vaginal, oral, or eye tissue. In certain other embodiments, the compositions of the present invention are applied to mild wounds or post-surgical sites to promote healing, to insect bites, lacquer, or similar skin conditions, or generally to relieve itching. In certain other embodiments, the composition of the present invention is applied to alleviate skin irritation. Stimuli are caused by ingredients in skin care products and cosmetics, such as retinoids and their derivatives, benzoyl peroxides, alpha hydroxy acids and their derivatives, salicylic acid, surfactants, natural plant extracts, sunscreen activators, urea and preservatives, It can be of external origin. Stimuli can be of other external origin, such as sunshine, wind or shaving. In addition, irritation can be caused by an inherent disease state such as acne, injection, atopic dermatitis and other disease states. In another embodiment, the compositions of the present invention may be useful for reducing gingival erythema. The extract may also be suitable for use in reducing the appearance of peripheral vasodilatation or spider veins, decreasing injection, skin discolorations and skin discolorations. In certain embodiments, the compositions of the present invention are formulated for the purpose of improving hair health, for promoting hair growth or delaying hair loss, for the prevention or treatment of dandruff, for the prevention or treatment of boring or seborrheic scalp salts, Lt; / RTI &gt; to the scalp, or both. In another embodiment, the compositions of the present invention are used for the prevention or treatment of redness or hypersensitivity of the gums, for the reduction of periodontitis, for the treatment or prevention of gingivitis, for the reduction of the dry mouth symptoms or the feeling of dry mouth, . In another embodiment, the compositions of the present invention are used for the treatment, prevention or reduction of the appearance of eye irritation or irritated eyes, for the prevention or treatment of conjunctivitis, for reduction of eye moisture, It is applied to the eyes. In another embodiment, the compositions of the present invention are applied to the vaginal mucosa for the prevention or treatment of elastic loss, irritation or dryness symptoms.

The composition of the present invention may comprise any suitable optional cosmetic ingredient as described above and may be in any suitable cosmetic form (e.g., a solution, suspension, bar, cleanser, lotion, cream, essence , Facial mask, etc.). In addition, the compositions of the present invention may comprise one or more additional skin lightening agents, anti-inflammatory agents, collagen promoters and / or tropoelastin promoters, as described above. In certain preferred embodiments, the compositions comprise one or more additional skin lightening agents. In certain preferred embodiments, the compositions comprise one or more additional anti-inflammatory agents. In certain preferred embodiments, the composition comprises one or more additional collagen promoters. In certain preferred embodiments, the compositions comprise one or more additional tropoelastin promoters.

Example

The following test methods were used in the examples:

Melanin synthesis inhibition test

Control samples of B16 (F10) mouse melanoma cells were prepared and harvested as described below, without any test samples added and without exposure to UVB (untreated control). Other control samples were prepared and harvested as described below, and exposed to UVB (treated control) as described below, without the addition of test samples. One or more samples of B16 (F10) cells were prepared and each was pre-treated with a test sample (e.g., E1) as described below and then exposed to UVB. Upon treatment, UVB-stimulated melanin formation and test compounds in the cells were evaluated based on their ability to inhibit or slow down melanogenesis. The cells were lysed for protein determination at 595 nm and melanin content at 470 nm. The percent inhibition achieved by the test compound was compared to the treated control to determine the efficacy of the test compound.

Test procedure:

Claim in 1, mouse melanoma B16 (F10) cells, 1 million cells were seeded in 60 mm plates at a density were incubated 37 ℃, in 5% CO ₂ for 48 hours per plate. On day 2, cells with a confluency ratio of 90-100% were treated with the test compound (at test compound sample only) at a given concentration (e.g., 25 ug / mL) for 2 hours UVB 200 mJ / cm &lt; ² &gt; (for the test sample and the treated control). Cells were harvested on day 3 (24 hours after UVB irradiation for test and treated controls) and lysed in protein lysis buffer (50 mM Tris, pH 8, 2 mM EDTA, 150 mM NaCl, and 1% Triton (Triton x 100 - nonionic surfactant purchased from BioRad, catalog number: 161-0407) and centrifuged. The resulting supernatant was mixed well with the protein dye analyzer (Bio-Rad protein assay reagent) and the optical density of the sample at 595 nm (protein analysis OD (Molecular Devices, VERSAmax) ) Were measured. After removing the supernatant, the remaining cell pellet was dissolved in alkaline DMSO buffer and the resulting solution was used for melanin absorption analysis at 470 nm to determine the melanin OD.

Three samples of the untreated control, the treated control, and each test sample were prepared, and the melanin and protein OD were measured for each. Normalized melanin was calculated for each of the untreated control (3 samples), the treated control (3 samples) and the test sample (3 samples for each test compound) in the following equation:

Normalized melanin = melanin assay OD / protein assay OD.

Normalized melanin averages of the untreated controls were calculated (sum of the three calculated values / 3), and the normalized melanin averages of the treated control were similarly calculated.

Induced values of the control group were calculated by the following equation:

Induced value of control = normalized melanin mean of treated control - normalized melanin mean of untreated control.

The derived values of each of the test samples were then calculated by the following equation:

Induced value of test sample = normalized melanin of test sample - normalized melanin mean value of untreated control.

Subsequently, the percent inhibition of each of the test samples was calculated by the following equation:

100 x [(Induced value of control group - Induced value by test sample) / derived value of control group]. The average percent inhibition is calculated by dividing the sum of the three% inhibition percent values generated by each test sample by three.

The calculation procedure for the inhibition rate is illustrated by a theoretical example, and the following table is a reference.

Skin skin equivalence model as skin lightening test (ΔL)

Skin epidermal equivalent tissues were obtained commercially from MatTek ' s MelanoDerm &lt; (TM) &gt; System and used in the following tests. The Mattechs melanoderm system consists of normal human-derived epidermal keratinocytes (NHEK) and melanocytes (NHM), which are cultured to form a multi-layered, highly differentiated human epidermal model. Specifically, MEL-300-B microstructures, each 9 mm in diameter, were used in the following test.

The appropriate vehicle and the test material prepared at the test concentration were topically applied daily to the skin model and the experiment was continued for 8 days. Measurements were performed on day 9.

Photographs were taken with a digital camera and tissue darkening endpoints were measured with macroscopic and microscopic views. The degree of lightening (L-value) for each tissue was measured using a spectrophotometer (Konica Minolta CM-2600d). The? L (the degree of lightening compared to the control) for each of the test samples is calculated by the following equation:

? L = (L-value of the treated sample) - (L-value of the control sample).

Cell viability test

The MTT assay described below was used to assess the cell viability of the tissue during the test. The MTT tissue survival analysis is a colorimetric assay system that measures the reduction of yellow methyl thiazolyl diphenyl-tetrazolium bromide (MTT) to an insoluble purple product by living mitochondria.

The percent of living cells remaining at the end of the test was measured using skin epidermal tissue that was already used to measure the degree of lightening of each test substance and untreated tissue. The skin epidermal tissue after the lightness test was incubated with the MTT reagent for 3 hours. After incubation, the cells were lysed by adding extraction buffer and allowed to stand overnight. Samples were read at a wavelength of 570 nm using a plate reader and expressed as% cell viability for the control compared to the untreated control. A decrease in cell viability of less than 30% for those of the control group is considered to indicate a significant cytotoxicity caused by the test substance. The amount of purple color produced is directly proportional to the number of living cells.

The following examples illustrate the preparation and efficacy of wood extracts from Pauluniatomentosa.

Example 1

Four extracts of 20 mg or more from each of the pauloni astratomes were obtained from the plant extract bank of the Korea Research Institute of Biosciences & Biotechnologies, which is a combination of parts of the plant or individual Parts. They originated from a combination of stem / bark / branch (E1), leaf (C1), bark (C2) and stem (E2). All extracts were prepared using methanol under sonication at &lt; RTI ID = 0.0 &gt; 50 C. &lt; / RTI &gt;

Example 2

The following examples illustrate the preparation of the PaulowniaTomentosa wood extract (E3) according to certain embodiments of the present invention.

Pauluniatomentosa wood powder was obtained from the Kurosawa Kiri Wood Supply Shop in Kitakata City, Japan. Ten grams (10 g) of dry wood powder was suspended in 250 mL of reagent grade ethanol and stirred at room temperature for 72 hours. The resulting suspension was filtered and the filtrate was dried at 30 &lt; 0 &gt; C using a rotary evaporator under reduced pressure. The dry crude extract was obtained in 3.5% yield (350 mg). The crude extract was dissolved in methanol at a concentration of 1% and treated with activated charcoal (700 mg) at room temperature for 5 minutes. The suspension was filtered through 0.45 micrometer filter paper. The filtrate was dried to obtain 210 mg (yield from crude extract: 60%) of E3, a visually brighter substance.

Example 3

The following examples illustrate the preparation of PaulowniaTomentosa wood extract (E4) essentially free of beta -sitosterol and uric acid.

Deionized grade water (2.4 mL) was added to the Pauluniatomentosa stem / bark / eggplant extract (E1, 24 mg) from Example 1 above and sonicated at room temperature for 5 minutes. The resulting suspension was filtered through a 0.45 mu filter cartridge and the filtrate was dried by lyophilization to yield a water soluble component (E4; 10.3 mg) in 43% yield. HPLC analysis indicates that the composition is essentially free of beta -sitosterol and uric acid. The detectable amount of any one of the compounds is not present in E4. The limit of detection (lod value) of? -sitosterol was 9 ppm (w / v) and that of uronic acid was 0.5 ppm (w / v).

Example 4

The following examples illustrate skin lightening properties of the extracts of E1-E5 of Pauluniatomentosa and of Comparative Examples C1-C2.

All seven extracts were tested at different concentrations up to 2% (as listed in Table 1) through a skin epidermal equivalent model as a skin lightening test (? L) as described above.

The cytotoxic potential of all extracts was measured by MTT assay and the percent reduction of cell viability was calculated as compared to the control, where a reduction of cell viability of> 30% represents a significant cytotoxicity problem. The results are shown in Table 1 below.

A simple first step extraction of wood powder using water only as solvent at room temperature was also performed (E5) which did not lead to activity in the skin lightening test. More thorough extraction (additional heating, agitation, etc.) is believed to be able to generate activity.

[Table 1]

Example 5

The following examples illustrate the melanin synthesis inhibitory properties associated with the wood extract of Pauluniatomentosa.

Stem / bark / eggplant extract (E1) and wood powder extract (E3) were tested for inhibition of melanin synthesis according to the melanin synthesis inhibition test described above and also for thyrosinase inhibition. The resulting measurements showed that the skin-lightening effects of E1 and E3 were at least partially associated with inhibition of melanin formation but not with tyrosinase inhibition. The IC50 values of extracts E1 and E3 were 30 and 40 μg / mL for inhibition of melanin formation, with no thyrosinase inhibition from either extract.

Example 6

NF-κB inhibition assay

NF-κB promoter assay is performed as follows: rat myocardial cell H9C2 cells were purchased from ATCC (Manassas, Va.). Dulbecco's modified Eagle's medium (DMEM, Carlsbad, Calif., USA) supplemented with 10% fetal bovine serum, 100 units / ml penicillin, and 50 ug / ml streptomycin (Invitrogen Life Technologies, Carlsbad, Lt; / RTI &gt; Life Technologies). Typically, 1 x 10 ⁴ cells grown in 96-well plates were transiently transfected with 0.45 ug of total DNA per well using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA) Transfected. In all transfections, in addition to the luciferase promoter, a preparation with the thymidine kinase promoter and the Renilla luciferase reporter gene (pRL-TK, Promega, Madison, Wis.) Was included as an internal control . One day after transfection, cells were treated with an indicated concentration of extract and stimulated with approximately 100 ng / mL tumor necrosis factor-alpha (TNF alpha, Sigma-Aldrich, St. Louis, Mo.) for approximately 24 hours The cells were then lysed for luciferase assay using the Dual-Luciferase Reporter System from Promega (Madison, Wis., USA) according to the manufacturer's protocol. Briefly, the luminescence meter LMAX from Molecular Devices (Sunnyvale, Calif., USA) was used to first detect firefly luciferase activity (representing NF-κB promoter activity), followed by Renilla luciferase ) Were measured. The ratio of the two activities of the luciferase activity (RLU) was used to evaluate the activity of each promoter.

NF-KB inhibition = [1- (RLU _sample / RLU _control )] * 100

Here, the RLU _sample and the RLU _control are the normalized luciferase activity ratios of the sample and the control, respectively.

The NF-kB inhibition assay described above was performed on various amounts of extracts E3 and E5. In Tables 2a and 2b, normalized NF-kB gene reporter activity and NF-kB inhibition (%) are reported.

[Table 2a]

[Table 2b]

Example  7

Anti-inflammatory effects on the release of UV-induced proinflammatory mediators in reconstituted epidermis

The efficacy of the extract of Paulonii Tontentosa (E3) was evaluated for its local anti-inflammatory activity in human epidermal equivalents. A multi-layered and differentiated epidermal equivalent (EPI 200 HCF) consisting of normal human epidermal keratinocytes was purchased from MatTek (Ashland, Mass., USA). Upon storage, the epidermal equivalent was incubated at 37 [deg.] C for 24 hours in a maintenance medium without hydrocortisone. 1000W-Oriel solar simulator with solar ultraviolet light (1-mm shot) WG 320 filter; Two hours before exposure to the applied UV dose: 70 kJ / m ² when measured at 360 nm, the equivalent was topically treated with an extract of Pauluniatomentosa in a 70% ethanol / 30% propylene glycol vehicle (2 mg / Cm2). Equivalents were incubated for 24 h at 37 ° C in maintenance media and then incubated with IL-8 and IL-1α cytokines (commercially available from Millipore Corp., Wilmington, Mass., USA) Release.

[Table 3]

[Table 4]

Based on the above examples, topical application of the extract of Pauluniatomentosa could significantly reduce the UV-stimulated release of the inflammatory mediator. Thus, it is expected that the extract of Pauluniatomentosa will provide effective anti-inflammatory effects when applied to the skin.

Example 8

Inhibition of reactive oxygen species formation in the reconstructed epidermis UV-induced hydrogen peroxide formation is described in Martin et al., Arch Dermatol Res. (2008) 300: 69-80], and were determined in reconstituted epidermal and human epithelial cell lines, KB. A multi-layered and differentiated epidermal equivalent (EPI 200 HCF) consisting of normal human epidermal keratinocytes was purchased from MatTek (Ashland, Mass., USA). Upon storage, the epidermal equivalent was incubated at 37 [deg.] C for 24 hours in a maintenance medium without hydrocortisone. After 24 hours, the tissues were incubated with 5 [mu] M hydrogen peroxide-sensitive fluorescent probe 5- (and -6) -chloromethyl-2 ', 7'-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) Invitrogen Corporation, Carlsbad, Calif.) For 30 minutes. After incubation, the plates were rinsed to remove excess probes and the treatments were topically treated (2 mg / cm ² ) with the extract of Pauluniatomentosa (E3) in a 70% ethanol / 30% propylene glycol vehicle. Plates were immediately read in a fluorescent plate reader set at a 485 nm excitation / 530 nm emission wavelength to detect basal peroxide formation. The plates were then exposed to UV (1000 W-Oriel sun simulator with 1 mm short WG 320 filter; 4.2 kJ / m ^{2 as} measured at an applied UV dose: 360 nm). Plates were read at 60 min after UV exposure.

[Table 5]

Based on the above examples, topical application of the extract of Pauluniatomentosa could significantly reduce the UV-stimulated production of ROS in the reconstructed epidermis. Thus, when applied to the skin, the extract of Pauluniatomentosa is expected to provide protection against the induction of ROS from sunlight irradiation.

Example 9

Inhibition of reactive oxygen species formation in human epithelial cells

KB cells obtained from ATCC (ATCC # CCL-17, Manassas, Va.) Were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen Corporation, San Diego, CA) And plated on 96 well tissue culture treated plates at a density of 5000 cells / well. After 48 hours, the cells were incubated with 5 [mu] M hydrogen peroxide-sensitive fluorescent probe 5- (and -6) -chloromethyl-2 ', 7'-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) Invitrogen Corporation, Carlsbad, Calif.) For 30 minutes. After incubation, the plates were rinsed to remove excess probes and the extract of Pauluniatomentosa (E3) was added at the indicated concentrations. Plates were immediately read in a fluorescent plate reader set at a 485 nm excitation / 530 nm emission wavelength to detect basal peroxide formation. The plates were then exposed to UV (1000 W-Oriel sun simulator with 1 mm short WG 320 filter; 4.2 kJ / m ^{2 as} measured at an applied UV dose: 360 nm). Plates were read at 60 min after UV exposure.

[Table 6]

Based on the above examples, treatment with the extract of Pauluniatomentosa could significantly reduce the UV-stimulated production of ROS in human epithelial cells. Thus, when applied to the skin, the extract of Pauluniatomentosa is expected to provide protection against the induction of ROS from sunlight irradiation.

Example 10

Protection from elastase degradation

Human leukocyte elastase (HLE) was purchased from Sigma (St. Louis, Missouri, USA) and incubated with phosphate buffered saline (PBS, Invitrogen life Technologies, Carlsbad, CA) / mL &lt; / RTI &gt; Soluble bovine ligament elastin labeled with BODIPY FL dye was purchased from Molecular Probes, Inc. (Eugene, Oreg., USA) and the fluorescence was quenched from the conjugate, Lt; RTI ID = 0.0 &gt; elastase. &Lt; / RTI &gt; Human leukocyte elastase (0.0625 U / ml), elastin substrate (25 ug / ml), and increasing concentrations of test material were incubated at 37 C for 2 hours. Fluorescence was measured at excitation at 490 nm and emission at 520 nm using a fluorescent plate reader Gemini from Molecular Devices (Sunnyvale, CA). The background fluorescence of the substrate alone was subtracted from each measurement. (E3) was prepared in DMSO at a stock solution concentration of 10 mg / ml and serially diluted. The extracts of Pauluniatomentosa inhibited HLE activity in a dose-dependent manner as shown in Table 7.

[Table 7]

This example demonstrates that the extract of Pauluniatomentosa can protect elastin fibers from damage and degradation.

Example 11

Inhibition of UV-induced MMP induction

The ability of the extract of Pauluniatomontosa (E3) to inhibit the UV-induced matrix metalloproteinase-1 and -9 (MMP-1 and -9) was assessed in a skin equivalent from normal human epidermal keratinocytes Respectively. MMP is an enzyme family that plays an important role in the physiological remodeling and pathological destruction of the extracellular matrix. It is well established that UV light at a dose of less than erythemal induced light induces MMP secretion in human skin, which in turn degrades extracellular matrix and plays a significant role in photoaging wrinkle formation, firmness and elasticity loss. G. J. Fisher, et al., J Investig Dermatol. Symposium Proceedings. 14 (1): 20-24 (2009).

In order to evaluate the ability of the extract of Pauluniatomontosa to inhibit UV induced MMPs, a multilayered and differentiated epidermis, epidermal equivalent (EPI 200 HCF) consisting of normal human epidermal keratinocytes was obtained from Mattech Ashland). Upon storage, the epidermal equivalent was incubated at 37 [deg.] C for 24 hours in a maintenance medium without hydrocortisone. Equivalents were dissolved in 70% ethanol (10% ethanol) for 2 hours before exposure to solar UV light (1000 W-Oriel solar simulator with 1-mm Schott WG 320 filter; applied UV dose: 70 kJ / / RTI &gt; (2 mg / cm2) with the extract of Pauluniatomontosa (E3) in a 30% propylene glycol vehicle. Equivalents were incubated for 48 hours at 37 [deg.] C using maintenance media, and supernatants were analyzed for MMP-1 and -9 using a commercially available kit (R & D Systems, Minneapolis, Minn.). The data in Table 8 represents the average of two independent experiments, and each experimental condition is performed using dual tissue.

[Table 8]

[Table 9]

Based on the above examples, topical application of the extract of Paulownia tontentosa could significantly reduce the UV-stimulated release of MMP-1 and -9. Thus, when applied to the skin, the extract of Pauluniatomentosa is expected to provide protection against the induction of MMP-1 and -9 after exposure to sunlight.

Example 12

Inhibition of TNF-α-induced MMP induction

In order to evaluate the ability of the extract of Pauluniatomontosa (E3) to inhibit TNF-α induced MMP, a multi-layered and differentiated skin, epidermal equivalent (EPI 200 HCF) consisting of normal human epidermal keratinocytes Were purchased from Mattech (Ashland, Mass., USA). Upon storage, the epidermal equivalent was incubated at 37 [deg.] C for 24 hours in a maintenance medium without hydrocortisone. Equivalents were topically treated (2 mg / cm 2) with the extract of Pauluniatomentosa (E3) in a 70% ethanol / 30% propylene glycol vehicle 2 hours before treatment with TNF-α (100 ng / Equivalents were incubated for 48 hours at 37 [deg.] C using maintenance media, and supernatants were analyzed for MMP-1 and -9 using a commercially available kit (R & D Systems, Minneapolis, Minn.).

[Table 10]

[Table 11]

Based on the above examples, topical application of the extract of Pauluniatomentosa could significantly reduce the TNF-a-promoted release of MMP-1 and -9. Thus, when applied to the skin, the extract of Pauluniatomentosa is expected to provide protection against the induction of MMP-1 and -9.

Example 13

The tropoelastin promoter assay was performed using Tanacetum paultanium (Extract of Feverpearn without Parthenolide from Integrative Botanical Technologies, Osing, NY, USA).

Tannacetum parterenum was diluted in cell culture medium (DMEM medium of Invitrogen, San Diego, Calif., USA) and diluted in DMSO to the concentration of "active" . Compounds were added to transfected H9C2 cells and incubated for 24 hours. Test samples were compared with each control. The results are shown in Table 12 below.

[Table 12]

As can be seen from the results shown in Table 12, pauloniatistomentosa and tanacetumpartenium showed 32% and 2% tropoelastin promoted change rates (%) for the respective control groups, respectively. In contrast, the combination of both Pauluniatomentosa and Tanacetum parterenum showed a 55% increase in tropoelastin promoting activity relative to the vehicle control. This was far greater than the simple additive effect in performance.

A similar synergistic effect was observed when the concentration of tanacetum phthalonium was increased from 0.002% to 0.005%. In addition, the higher concentration of Tanacettum parteren showed a 2% change (%) with respect to the control in the tropoelastin promoting, while the combination of Pauluniatomentosawa and Tanacetum fartenium resulted in a higher (%) Of 62% relative to that of the control.

These data demonstrate that the combination of (PaulowniaTomentosa and tropoelastin promoter (Tanacetum pharrhenium) produces a surprising and synergistic increase in tropoelastin promoting activity.

Example 14: Isolation and identification of paulonin

Isolation of the major component (paurounin) from the pauloniatistomentosa was achieved using a combination of fractionation and preparative HPLC steps. A sample of 170 mg with the same residence time and UV spectrum as that of the main signal of the extract was obtained. Spectroscopic studies have confirmed their identity with faurolone. The purity of the isolated pawloinin was determined to be 98%.

Example 15

The antioxidant activity of paurolone was established through the analysis of inhibition of the reactive oxygen species formation described above. In this study, primary human keratinocytes were used in place of human epithelial (KB) cells. Keratinocytes were plated on 96 well tissue culture treated plates at a density of 5000 cells / well in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen Corporation, San Diego, Calif.) Supplemented with 10% fetal bovine serum . After 48 hours, the cells were incubated with 5 [mu] M hydrogen peroxide-sensitive fluorescent probe 5- (and -6) -chloromethyl-2 ', 7'-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) Invitrogen Corporation, Carlsbad, Calif.) For 30 minutes. After incubation, the plates were rinsed to remove excess probes and the poulonin was added at the indicated concentration. Plates were immediately read in a fluorescent plate reader set at a 485 nm excitation / 530 nm emission wavelength to detect basal peroxide formation. The plates were then exposed to UV (1000 W-Oriel sun simulator with 1 mm short WG 320 filter; 4.2 kJ / m ^{2 as} measured at an applied UV dose: 360 nm). Plates were read after 60 minutes of UV exposure and data were recorded in mean fluorescent unit (MFU). The results are shown in Table 13 below.

[Table 13]

On the basis of the examples, treatment with fauroninin could significantly reduce the UV-induced production of ROS in human epithelial cells. Thus, therefore, when applied to the skin, it is expected that paurolonin will provide protection against the induction of ROS from sunlight irradiation, thus improving skin firmness, improving skin texture, improving appearance of wrinkles in skin, and Would be expected to provide significant activity for the reduction of signs of aging such as treatment for external attack on the skin.

Example 16

The following skin care compositions were prepared using the ingredients shown in Table 14 according to the present invention.

[Table 14]

The composition was prepared as follows: Purified water was added to the main tank at a temperature of 20-40 C with gentle stirring. Bersen NA (Dissodium EDTA) was then added to the main tank. Stirring in the tank was stopped and Ultrez 10 (carbomer) was added by evenly coating the top of the water mixture. The mixture was soaked and stirring and heating were started. The mixture was heated to 55-60 &lt; 0 &gt; C and mixed for an additional 15 minutes or until homogeneous.

The oil phase was prepared by the addition of pin Solv TN (C12-15 alkyl benzoate) to a clean, suitable phase vessel, where it was stirred and heated to achieve 55-60 ° C. After such a temperature has been achieved, Breeze 72 and 721 (stearate-2, -21, respectively), miglyol (caprylic / capric triglyceride), Emery 917 (glycerin) ) Were added and mixed at 55-60 &lt; 0 &gt; C until added to the main tank.

The oil phase was added to the main tank with increasing stirring and heating was discontinued. The resulting mixture was mixed at high speed for 10-20 minutes. At 50 DEG C or less, Dimethicone (Dow Corning Silicone Fluid) was added. The batch mixture was then cooled to 40 DEG C and Phenonip XB (preservative mix) was added. The mixture was mixed for an additional 10 minutes or until homogeneous. Sodium hydroxide was added rapidly (target pH = 5.4) with mixing for an additional 10 minutes or until a uniform pH was achieved.

The active water premix includes transcutol CG, butylene glycol, citric acid, and

The true tunga extract was added to a separate beaker and mixed well until homogeneous.

The active water premix is added to the main phase of the main tank,

The final formulation was made by mixing for an additional 10-20 minutes until completely dissolved or uniform. The final volume was made up with water, the formulation was mixed for 10 minutes and the pH was recorded.

Samples of the composition were placed in an oven at 50 DEG C for 2 weeks, which showed excellent primary stability.

Example 17

The following skin care compositions were prepared using the ingredients shown in Table 15 according to the present invention.

[Table 15]

The composition was prepared as follows: Purified water was added to the main tank, followed by the addition of disodium EDTA and mixing until EDTA dissolved. Ammonium acryloyl dimethyl taurate / VP copolymer was sprayed inside and the resulting mixture was heated to 70-75 占 폚. After the set temperature was achieved, the mixture was added with cetearyl olivate / sorbitan olivate and stearic acid while stirring at the set temperature for 5 minutes.

The active water premix was prepared by dissolving the true tungstate extract in butylene glycol at 40-50 ° C in a separate container. Polyacrylate 13, and polyisobutene and polysorbate 20 were added to the paulownia wood mix and then mixed until uniform. The temperature was lowered to 35-40 &lt; 0 &gt; C and set aside until ready to be added to the main tank.

The chlorphenesine premix was prepared by adding chlorophenesin to butylene glycol in a separate vessel and heating to 35 ° C followed by the addition of methyl isothiazolinone. The resulting mixture was heated to 50-55 &lt; 0 &gt; C and held at this temperature until ready to be mixed into the main tank.

The oil phase was prepared by adding cyclopentasiloxane and dimethicone crosspolymer to cyclopentasiloxane and cyclohexasiloxane while heating in a separate vessel and heating to 55-60 DEG C until homogeneous. Ethylhexyl glycerin was then added, mixed until homogeneous, and then stearic acid was added, keeping the temperature between 55-60 ° C.

The oil phase was then slowly added to the main tank with vigorous stirring at a temperature of 70-75 占 폚. Dimethicone and dimethicone were added to the main batch and the resulting mixture was stirred for 20 minutes or until homogeneous, after which heating was discontinued. The main pH was adjusted to between 5.0-5.5 with sodium hydroxide. The chlorphenesine phase was added slowly at 50-55 &lt; 0 &gt; C while maintaining the stirring. The mixture was cooled to 35-40 DEG C, and fragrance, FD &amp; C red and D &amp; C yellow were added and mixed well while maintaining the temperature.

The final formulation was achieved by slowly adding the active water premix to the main tank while gently mixing. The mixture was further mixed for 10-20 until homogeneous. The final volume was made up with water, the formulation was mixed for 10 minutes and the pH was recorded.

Samples of the composition were placed in an oven at 50 DEG C for 2 weeks, which showed excellent primary stability.

Claims (20)

Improving skin firmness, improving texture of the skin, improving the appearance of wrinkles in the skin, treating external aggression in the skin, and combinations of two or more of these. A method of improving skin aging symptoms selected from the group comprising: administering a therapeutically effective amount of Paulownin to the skin to improve skin firmness, improve skin texture, improve wrinkle appearance on the skin, A method of improving skin aging symptoms comprising applying to human skin an amount effective to ameliorate at least two combinations. 2. The method of claim 1, wherein the applying step comprises applying greater than 0% to about 20% of poulonin to the skin that requires improvement of aging symptoms. 2. The method of claim 1, wherein the applying step comprises applying at least about 20% by weight of the paurounin to the skin requiring improvement in signs of aging. 3. The method of claim 1, wherein the applying step comprises applying at least about 50% by weight of the paurounin to the skin requiring improvement in signs of aging. 2. The method of claim 1, wherein the applying step comprises applying at least about 90% by weight of poulonin to the skin requiring improvement in signs of aging. 2. The method of claim 1, wherein said applying comprises applying from about 0.01 to about 1% of poulonin to said skin requiring improvement of aging symptoms. 2. The method of claim 1, wherein said applying comprises applying from about 0.1 to about 5% of poulonin to said skin requiring improvement of aging symptoms. The method of claim 1, wherein said application step comprises applying a composition comprising a faurolin and a carrier to said skin requiring improvement in an aging indication, said composition being in the form of a solution, suspension, lotion, cream, serum, Signs of skin aging, in the form of sticks, sprays, ointments, liquid waxes, soap bars, shampoos, hair conditioners, pastes, foams, powders, mousses, shaving creams, hydrogels or film- &Lt; / RTI &gt; 9. The method of claim 8, wherein the composition further comprises a tropoelastin promoter. 10. The method of claim 9, wherein the tropoelastin promoter is selected from the group consisting of blackberry extract, cotinus extract, feverfew extract, Phyllanthus niruri extract and combinations of two or more thereof Lt; RTI ID = 0.0 &gt; a &lt; / RTI &gt; skin aging symptom. 9. The method of claim 8, wherein the composition further comprises a collagen promoter. 12. The method of claim 11, wherein the collagen promoter is a non-retinoid collagen promoter. The non-retinoid collagen promoter according to claim 12, wherein the non-retinoid collagen promoter is selected from the group consisting of extracts of Tanacetum parthenium, extracts of Centella asiatica, extracts of Siegesbeckia orientalis, Extracts, and combinations of two or more of the foregoing. 12. The method of claim 11, wherein the collagen promoter is a retinoid. 15. The composition of claim 14 wherein the retinoid is selected from the group consisting of retinol, retinal, retinyl acetate, retinyl propionate, retinyl linoleate, retinyl palmitate, and combinations of two or more thereof. How to Improve the Signs of Aging. The method of claim 1, wherein the improvement of the aging symptom comprises improvement of the skin firmness, wherein the application step comprises applying an effective amount of foulonin to the human skin, which requires improvement of the skin firmness, How to Improve Signs. 17. The method of claim 16, wherein the human skin that requires improvement in skin firmness is selected from the group consisting of sagging, loose, loose, rough, wrinkled, thinned, A method of improving skin aging symptoms comprising skin having the above combination. 3. The method of claim 1, wherein the improvement of the aging symptom comprises an improvement in the appearance of wrinkles in the skin, wherein the application step comprises applying an effective amount of foulonin to the human skin that requires improvement in appearance of wrinkles in the skin &Lt; / RTI &gt; 19. The method of claim 18, wherein the human skin that requires improvement in the appearance of wrinkles in the skin comprises skin with wrinkles, fine wrinkles, or combinations thereof. 9. The method of claim 8, wherein the composition further comprises a sunscreen.